Heterogeneity in transmissibility and shedding SARS-CoV-2 via droplets and aerosols

3 Paul Z. Chen<sup>1</sup>, Niklas Bobrovitz<sup>2-4</sup>, Zahra Premji<sup>5</sup>, Marion Koopmans<sup>6</sup>, David N. Fisman<sup>7,8</sup>,

4 Frank X. Gu<sup>1,9</sup>\*

6 <sup>1</sup>Department of Chemical Engineering & Applied Chemistry, University of Toronto, Toronto,

7 Canada

1

2

5

8 <sup>2</sup>Temerty Faculty of Medicine, University of Toronto, Toronto, Canada

9 <sup>3</sup>Department of Critical Care Medicine, Cumming School of Medicine, University of Calgary,

10 Calgary, Canada

<sup>4</sup>O'Brien Institute of Public Health, University of Calgary, Calgary, Canada

12 <sup>5</sup>Libraries & Cultural Resources, University of Calgary, Calgary, Canada

13 <sup>6</sup>Department of Viroscience, Erasmus University Medical Center, Rotterdam, Netherlands

<sup>7</sup>Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto,

15 Canada

<sup>8</sup>Division of Infectious Diseases, Temerty Faculty of Medicine, University of Toronto, Toronto,

17 Canada

19

18 <sup>9</sup>Institute of Biomedical Engineering, University of Toronto, Toronto, Canada

\*Correspondence: f.gu@utoronto.ca

## **Abstract**

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

A growing number of studies provide insight into how SARS-CoV-2 spreads<sup>1-7</sup>. Yet, many factors that characterize its transmissibility remain unclear, including mechanistic correlates of overdispersion, viral kinetics, the extent to which respiratory droplets and aerosols carry viable virus and the infectiousness of asymptomatic, presymptomatic and pediatric cases<sup>7</sup>. Here, we developed a comprehensive dataset of respiratory viral loads (rVLs) via systematic review and investigated these factors using meta-analyses and modeling. By comparing cases of COVID-19, SARS and influenza A(H1N1)pdm09, we found that heterogeneity in rVL was associated with overdispersion and facilitated the distinctions in individual variation in infectiousness among these emergent diseases. For COVID-19, case heterogeneity was broad throughout the infectious period, although rVL tended to peak at 1 day from symptom onset (DFSO) and be elevated for 1-5 DFSO. While most cases presented minimal risk, highly infectious ones could spread SARS-CoV-2 by talking, singing or breathing, which shed virions at comparable rates via droplets and aerosols. Coughing shed considerable quantities of virions, predominantly via droplets, and greatly increased the contagiousness of many symptomatic cases relative to asymptomatic ones. Asymptomatic and symptomatic infections showed similar likelihoods of expelling aerosols with SARS-CoV-2, as did adult and pediatric cases. Children tended to be less contagious by droplet spread than adults based on tendencies of symptomatology rather than rVL. Our findings address longstanding questions on SARS-CoV-2 transmissibility and present pertinent considerations for disease control.

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

Main body The novel coronavirus SARS-CoV-2 has spread globally, causing the coronavirus disease 2019 (COVID-19) pandemic with more than 38.0 million infections and 1.0 million deaths (as of 13 October 2020)<sup>8</sup>. While the basic reproductive number has been estimated to be 2-3.6<sup>1,2</sup>, transmissibility of SARS-CoV-2 is highly overdispersed, with numerous instances of superspreading<sup>9-11</sup> and few cases (10-20%) causing many secondary infections (80%)<sup>4-6</sup>. Estimates indicate 40-87% of cases are asymptomatic or paucisymptomatic, which facilitates transmission<sup>2,3,12</sup>. Infectiousness begins around -3 to -2 DFSO and has been estimated to last 8-10 DFSO<sup>13-15</sup>. Hence, the temporal infectiousness profile of COVID-19 resembles that of influenza<sup>16</sup>, whereas its overdispersion is similar to that of severe acute respiratory syndrome  $(SARS)^{17}$ . For respiratory virus transmission, airway epithelial cells shed virions to the extracellular fluid before atomization (from breathing, talking, singing, coughing and aerosol-generating procedures) partitions them into a polydisperse mixture of droplets (>5 μm) and aerosols (≤5 μm) that are expelled to the ambient environment<sup>7</sup>. Based on mass, droplets tend to settle gravitationally, whereas aerosols remain suspended and travel based on airflow profiles. Although proximity has been associated with infection risk for COVID-19<sup>18</sup>, studies have also suggested that long-range aerosol spread occurs conditionally<sup>9-11</sup>. Despite these analyses, key factors that characterize the transmissibility of SARS-CoV-2 remain unclear. To investigate many of these factors, we synthesized evidence by systematic review, compared SARS-CoV-2 rVLs among subgroups, associated overdispersion, analyzed viral kinetics and modeled the likelihood of shedding viable virus via droplets and aerosols across respiratory activities, DFSO, case heterogeneity and subgroups. For inference on

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

transmissibility, we compared these analyses with those of SARS-CoV-1 (the most closely related human coronavirus) and A(H1N1)pdm09 (the most recent pandemic influenza virus), which spread by contact, droplets and aerosols<sup>19,20</sup>. **Systematic review** To develop the comprehensive dataset, we conducted a systematic review on quantitative VL measurements for respiratory specimens taken during the infectious periods of SARS-CoV-2 (-3 to 10 DFSO)<sup>13-15</sup>, SARS-CoV-1 (0-20 DFSO)<sup>21</sup> and A(H1N1)pdm09 (-2 to 9 DFSO)<sup>16</sup> (Methods). The systematic search (Supplementary Tables 1-5) identified 4,274 results. After screening and full-text review, 63 studies met the inclusion criteria and were used for analysis (Fig. 1) (n=9,692 total specimens), which included adult (n=5,124) and pediatric (n=1,593) cases and measurements for asymptomatic (n=2,378), presymptomatic (n=28) and symptomatic (n=7,231) infections. According to a hybrid Joanna Briggs Institute critical appraisal checklist, risk of bias was low to moderate for included studies (Extended Data Table 1). Meta-analysis and subgroup analyses of rVL For each study in the systematic dataset, we used specimen concentrations to estimate rVLs (Methods). We then performed a random-effects meta-analysis (Extended Data Fig. 1), which showed that, during the infectious periods, the expected rVL of SARS-CoV-2 was comparable to that of SARS-CoV-1 (p=0.148, two-sided Welch's t-test) but lesser than that of A(H1N1)pdm09 (p<0.0001). We also performed random-effects subgroup analyses for COVID-19 (Fig. 2), which showed that expected SARS-CoV-2 rVLs were consistent between pediatric and adult cases (p=0.861) and between symptomatic/presymptomatic and asymptomatic infections (p=0.951).

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

Association of heterogeneity in rVL with overdispersion Since few cases drive the transmission of SARS-CoV-2 (dispersion parameter k, 0.10-0.58)<sup>4-6</sup> and SARS-CoV-1  $(k, 0.16-0.17)^{17}$  whereas A(H1N1)pdm09  $(k, 7.4-14.4)^{22,23}$  spreads more homogeneously, we sought to find a mechanistic association for overdispersion. As an empirical estimate, k depends on myriad extrinsic (behavioral, environmental and invention) and host (host defenses) factors. However, since dispersion is similar across distinct outbreaks of a virus<sup>17</sup>, we hypothesized that an intrinsic virological factor mediates k for these emergent respiratory infections. We assessed heterogeneity in rVL. For all three viruses, rVLs best conformed to Weibull distributions (Extended Data Fig. 2), and we fitted the entirety of individual sample data for each virus in the systematic dataset (Fig. 3a, Extended Data Fig. 2n). While COVID-19 and SARS cases tended to shed lesser virus than those with A(H1N1)pdm09 (Extended Data Fig. 1), broad heterogeneity in rVL inverted this relationship for highly infectious individuals (Extended Data Fig. 3a-c). At the 90<sup>th</sup> case percentile (cp), the estimated rVL was 8.91 (8.82-9.00, 95% confidence interval [CI]) log<sub>10</sub> copies/ml for SARS-CoV-2, whereas it was 8.62 (8.47-8.76) log<sub>10</sub> copies/ml for A(H1N1)pdm09. Moreover, heterogeneity in rVL was similar among adult, pediatric, symptomatic/presymptomatic and asymptomatic COVID-19 cases (Extended Data Fig. 3d-g), with standard deviations (SDs) of 2.01-2.06 log<sub>10</sub> copies/ml (Extended Data Table 2). To investigate the relationship between k and heterogeneity in rVL, we performed a metaregression using each included study (Fig. 3b). The analysis showed a negative association (p=0.031, meta-regression slope t-test), indicating that heterogeneity in rVL intrinsically facilitated the distinctions in overdispersion among the emergent infections.

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

**Kinetics of SARS-CoV-2 rVL** To investigate dynamics, we delineated SARS-CoV-2 rVLs by DFSO and fitted the mean estimates to a mechanistic epithelial cell-limited model for viral kinetics (Fig. 3c, Methods). The outputs indicated that, on average, each productively infected cell in the airway epithelium shed SARS-CoV-2 at 1.11 (0.51-1.71, 95% CI) copies/ml day<sup>-1</sup> and infected up to 10.6 susceptible cells (Extended Data Table 3). The turnover rate for infected epithelial cells was 0.55 (0.23-0.87) days<sup>-1</sup>, while the half-life of SARS-CoV-2 in the respiratory tract was 4.35 (2.23-97.8) hours. By extrapolating the model to an initial rVL of 0-1 log<sub>10</sub> copies/ml, the estimated incubation period was 5.38-4.52 days, which agrees with epidemiological findings<sup>1</sup>. Conversely, the expected duration of shedding was 26.8 DFSO. Thus, SARS-CoV-2 replicated exponentially in the respiratory tract based on a mean rate constant of  $4.02 \times 10^{-7}$  ( $3.01 \times 10^{-7}$ - $5.03 \times 10^{-7}$ ) (copies/ml)<sup>-1</sup> day<sup>-1</sup> after infection. Around 1 DFSO, rVL peaked, as the number of infected epithelial cells reached equilibrium, and then diminished exponentially. As SARS-CoV-2 rVLs showed widespread heterogeneity across the infectious period, we fitted distributions for each DFSO (Fig. 3d), which showed that high rVLs also increased from the presymptomatic period before decreasing towards the end of the first week of illness. At the 90<sup>th</sup> cp, SARS-CoV-2 rVL peaked at 1 DFSO at 9.83 (9.12-10.61) log<sub>10</sub> copies/ml, an order of magnitude greater than the overall 90th-cp estimate (Extended Data Table 2). The estimate remained ≥9.33 log<sub>10</sub> copies/ml between 1-5 DFSO. At -1 DFSO, the 90<sup>th</sup>-cp rVL was 8.30 (6.88-10.02) log<sub>10</sub> copies/ml, while it was 7.92 (7.34-8.55) log<sub>10</sub> copies/ml at 10 DFSO (Extended Data Fig. 3h-s).

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

Likelihood of droplets and aerosols containing virions Since rVL is an intensive quantity, the volume fraction of virions is low and viral partitioning coincides with atomization, we used Poisson statistics to model likelihood profiles. To calculate an unbiased estimator of partitioning (the expected number of viable copies per particle), our method multiplied rVL estimates with the volumes of atomized particles and an assumed viability proportion of 0.1% after dehydration (Methods). When expelled by the mean COVID-19 case across the infectious period, respiratory particles showed minimal likelihoods of carrying viable SARS-CoV-2 (Fig. 4a,b). Aerosols (dehydrated aerodynamic diameter  $[d_a] \le 5 \mu m$ ) were <0.001% likely to contain a virion. Droplets also had low likelihoods: at  $d_a$ =40 µm, they were  $\leq$ 0.4% likely to contain a virion. COVID-19 cases with high rVLs, however, expelled particles with considerably greater likelihoods of carrying viable copies (Fig. 4a,b). For the 98th cp at 1 DFSO, 18.2% (8.8-27.6%) of aerosols ( $d_a$ =5 µm) contained at least one SARS-CoV-2 virion. For  $d_a$ >14.4 µm, droplets were >99% likely to contain virions, with large ones carrying tens to hundreds. **Shedding SARS-CoV-2 via respiratory activities** Using the partitioning estimates in conjunction with published profiles of the particles expelled by respiratory activities (Extended Data Fig. 4), we modeled the rates at which talking, singing, breathing and coughing shed viable SARS-CoV-2 across da (Fig. 4c-f). Among the nonpresenting activities, singing emitted virions most rapidly followed by talking and then breathing, although talking loudly was similar to singing (Extended Data Fig. 4c,d). These activities produced more aerosols than droplets, but particle size correlated with the likelihood of containing virions. Thus, talking, singing and breathing shed SARS-CoV-2 at similar rates via

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

aerosols and droplets: aerosols mediated 25.2-43.4% of the virions expelled by the nonpresenting activities (Fig. 4g). In comparison, coughing shed far greater quantities of virions (Fig. 4f), of which >99.9% were carried by droplets. We further examined the influences of case heterogeneity and disease course on expelling SARS-CoV-2 (Fig. 4h, Extended Data Fig. 5). The estimated total shedding rates (over all particle sizes) for a respiratory activity spanned ≥8.55 orders of magnitude on each DFSO; cumulatively from -1 to 10 DFSO, they spanned 11.2 orders of magnitude. Hence, most cases expelled a negligible number of SARS-CoV-2 virions by talking, singing or breathing. Shedding occurred most rapidly at 1 DFSO: for the 98th cp, singing discharged 31.5 (3.26-379, 95% CI) virions/min to the ambient environment, while talking emitted 4.67 (0.48-56.1) virions/min and breathing exhaled 1.27 (0.13-15.2) virions/min; these estimates were two orders of magnitude greater than those for the 86<sup>th</sup> cp. For the 98<sup>th</sup> cp at -1 DFSO, singing shed 1.31 (0.01-406) virions/min and breathing exhaled 5.24×10<sup>-2</sup> (5.28×10<sup>-4</sup>-16.3) virions/min. The estimates at 7-10 DFSO were comparable to these presymptomatic ones (Fig. 4h, Extended Data Fig. 5). At 1 DFSO, coughing expelled  $2.13\times10^6$  ( $2.20\times10^5$ - $2.56\times10^7$ ) virions/cough for the 98th cp, 90.4 (24.6-372) virions/cough for the 50th cp and 2.66 (0.65-13.1) virions/cough for the 25th cp (Extended Data Fig. 5c). At -1 and 10 DFSO, these estimates were reduced by ~2 orders of magnitude. Thus, most symptomatic cases shed considerable quantities of SARS-CoV-2 by coughing; a single cough accounted for the virions emitted by weeks of singing for a case. As indicated by similar mean rVLs (Fig. 2) and heterogeneities in rVL (Extended Data Table 2), asymptomatic, symptomatic/presymptomatic, adult and pediatric COVID-19 cases showed similar profiles for total shedding rates (Extended Fig. 6a-d). The estimates showed that the top 6.1%, 2.4% and 1.1% of pediatric cases shed  $\geq 1$  virion/min by singing, talking and

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

breathing, respectively, while 62.5% expelled ≥10 virions/cough. In general, highly infectious COVID-19 cases expelled virions more rapidly than did ones with A(H1N1)pdm09 (Extended Data Fig. 6f). **Discussion** This study provided comprehensive, systematic analyses of several factors characterizing the transmissibility of SARS-CoV-2. First, we evaluated the influence of heterogeneity in rVL. Our findings show that broad heterogeneity in rVL facilitates greater variation in individual infectiousness in the COVID-19 pandemic than was found in the 2009 H1N1 pandemic. For each respiratory activity, SARS-CoV-2 shedding rates span >11 orders of magnitude throughout the infectious period. While most COVID-19 cases present minimal transmission risk by talking, singing or breathing, highly infectious ones, including asymptomatic and presymptomatic infections, can spread SARS-CoV-2 through these activities. Our model estimates, when corrected to copies rather than virions, align with recent clinical findings for exhalation rates of SARS-CoV-2<sup>24</sup>. Moreover, the findings suggest that heterogeneity in rVL may be a virological factor generally associated with overdispersion for respiratory infections. In this case, rVL distribution may serve as an early correlate for transmission patterns, including superspreading, during outbreaks of novel respiratory viruses, providing insight for disease control before largescale epidemiological analyses empirically characterize k. Second, we analyzed SARS-CoV-2 kinetics during respiratory infection. While heterogeneity remains broad throughout the infectious period, the systematic dataset indicates that rVL tends to peak at 1 DFSO and be elevated for 1-5 DFSO, coinciding with the period of highest attack rates observed among close contacts<sup>25</sup>. These results indicate that transmission risk

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

tends to be greatest soon after illness rather than in the presymptomatic period, which concurs with large tracing studies (6.4-12.6% of secondary infections from presymptomatic transmission)<sup>26,27</sup> rather than early temporal models (~44%)<sup>14</sup>. Furthermore, our kinetic analysis suggests that, on average, SARS-CoV-2 reaches diagnostic concentrations 1.60-3.22 days after respiratory infection (-3.78 to -2.16 DFSO), assuming assay detection limits of 1-3 log<sub>10</sub> copies/ml, respectively, for nasopharyngeal swabs immersed in 1 ml of transport media. Third, we modeled the likelihood of shedding SARS-CoV-2 via aerosols. Talking, singing and breathing shed SARS-CoV-2 at comparable rates through droplets and aerosols (up to tens to hundreds of virions/min). As airborne spread is recognized as a key mode of transmission for A(H1N1)pdm09<sup>20</sup>, our model estimates and comparative analyses support, particularly for highly infectious cases, airborne spread as a transmission mode for SARS-CoV-2. While our models delineated aerosols from droplets at the classical threshold (d<sub>a</sub>=5 μm), recent reports show that, based on emission vectors and environmental conditions, respiratory particles larger than 5 μm can also travel >2 m in air<sup>28,29</sup>, further supporting the plausibility of the airborne transmission of SARS-CoV-2. However, with short durations of stay in well-ventilated areas, the concentration, and exposure risk, of aerosols remains correlated with proximity to infectious cases 18,28. Fourth, we assessed the relative infectiousness of COVID-19 subgroups. Since rVL distributions are similar among subgroups and the predominant source of aerosols is the nonpresenting respiratory activities (talking, singing and breathing), symptomatic and asymptomatic infections present similar risks for aerosol spread, as do adult and pediatric cases. However, most cases shed considerable numbers of virions via large droplets by coughing, a common symptom of COVID-19<sup>30</sup>. Thus, symptomatic infections tend to be significantly more contagious than asymptomatic ones, providing a reason as to why asymptomatic cases transmit SARS-CoV-2 at

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

lower relative rates<sup>3</sup>, especially in close contact<sup>31</sup>, despite similar rVLs and increased contact patterns. Accordingly, children (48-54% of symptomatic cases present with cough)<sup>32,33</sup> tend to be less contagious by droplet spread than adults (68-80%)<sup>30,33</sup> based on tendencies of symptomatology rather than rVL. Our study has limitations. The systematic search found a limited number of studies reporting quantitative specimen measurements from the presymptomatic period, meaning these estimates may be sensitive to sampling bias. Although additional studies have reported semiquantitative metrics (cycle thresholds), these data were excluded because they cannot be compared on an absolute scale due to batch effects<sup>34</sup>, limiting use in compound analyses. Furthermore, our analyses considered population-level estimates of the infectious periods and viability proportions, which omit individual variation in the dynamics of virus viability. Some patients shed SARS-CoV-2 with diminishing viability soon after symptom onset<sup>13</sup>, while others produce replication-competent virus for weeks<sup>35</sup>. It remains unelucidated how case characteristics and environmental factors affect the viability dynamics of SARS-CoV-2. Taken together, our findings provide a potential path forward for disease control. They highlight the disproportionate role of high-risk cases, settings and circumstances in propelling the COVID-19 pandemic. Since highly infectious cases, regardless of age or symptomatology, can rapidly shed SARS-CoV-2 via both droplets and aerosols, airborne spread should also be recognized as a transmission risk, including for superspreading. Strategies to abate infection should limit crowd numbers and duration of stay while reinforcing distancing and then widespread mask usage; well-ventilated settings can be recognized as lower risk venues. Coughing sheds considerable quantities of virions for most infections, while rVL tends to peak at 1 DFSO and can be high throughout the infectious period. Thus, immediate, sustained selfisolation upon symptom presentation is crucial to curb transmission from symptomatic cases. While diagnosing COVID-19, qRT-PCR can also help to triage contact tracing, prioritizing patients with higher specimen measurements: for nasopharyngeal swabs immersed in 1 ml of transport media,  $\geq$ 7.14 (7.07-7.22, 95% CI) log<sub>10</sub> copies/ml corresponds to  $\geq$ 80<sup>th</sup> cp. Doing so may identify asymptomatic and presymptomatic cases more efficiently, a key step towards mitigation as the pandemic continues.

## 254 References 255 Li, Q. et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected 1 256 pneumonia. N. Engl. J. Med. 382, 1199-1207, doi:10.1056/NEJMoa2001316 (2020). 257 2 Hao, X. et al. Reconstruction of the full transmission dynamics of COVID-19 in Wuhan. 258 Nature **584**, 420-424, doi:10.1038/s41586-020-2554-8 (2020). 259 3 Li, R. et al. Substantial undocumented infection facilitates the rapid dissemination of novel 260 coronavirus (SARS-CoV-2). Science **368**, 489-493, doi:10.1126/science.abb3221 (2020). 261 4 Endo, A., Abbott, S., Kucharski, A. J. & Funk, S. Estimating the overdispersion in 262 COVID-19 transmission using outbreak sizes outside China. Wellcome Open Research 5, 263 doi:10.12688/wellcomeopenres.15842.1 (2020). 264 5 Laxminarayan, R. et al. Epidemiology and transmission dynamics of COVID-19 in two 265 Indian states. Science, eabd7672, doi:10.1126/science.abd7672 (2020). 266 6 Bi, Q. et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their 267 close contacts in Shenzhen, China: a retrospective cohort study. Lancet Infect. Dis. 20, 268 911-919, doi:10.1016/s1473-3099(20)30287-5 (2020). 269 Organization, W. H. Transmission of SARS-CoV-2: implications for infection prevention 7 270 precautions (scientific brief). July 9, 2020. 271 Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in 8 272 real time. Lancet Infect. Dis. 20, 533-534, doi:10.1016/S1473-3099(20)30120-1 (2020). 273 9 Shen, Y. et al. Community outbreak investigation of SARS-CoV-2 transmission among 274 bus riders in Eastern China. JAMA Intern. Med., doi:10.1001/jamainternmed.2020.5225 275 (2020).

276 10 Lu, J. et al. COVID-19 outbreak associated with air conditioning in restaurant, Guangzhou, 277 China, 2020. Emerg. Infect. Dis. 26, 1628-1631, doi:10.3201/eid2607.200764 (2020). 278 11 Hamner, L. et al. High SARS-CoV-2 attack rate following exposure at a choir practice -279 Skagit County, Washington, March 2020. MMWR Morb. Mortal. Wkly. Rep. 69, 606-610, 280 doi:10.15585/mmwr.mm6919e6 (2020). 281 12 Oran, D. P. & Topol, E. J. Prevalence of asymptomatic SARS-CoV-2 infection: a narrative 282 review. Ann. Intern. Med. 173, 362-367, doi:10.7326/M20-3012 (2020). 283 13 Wolfel, R. et al. Virological assessment of hospitalized patients with COVID-2019. Nature 284 **581**, 465-469, doi:10.1038/s41586-020-2196-x (2020). 285 He, X. et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat. 14 286 Med. 26, 672-675, doi:10.1038/s41591-020-0869-5 (2020). 287 15 Arons, M. M. et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled 288 nursing facility. N. Engl. J. Med. 382, 2081-2090, doi:10.1056/NEJMoa2008457 (2020). 289 16 Ip, D. K. et al. Viral shedding and transmission potential of asymptomatic and 290 paucisymptomatic influenza virus infections in the community. Clin. Infect. Dis. 64, 736-291 742, doi:10.1093/cid/ciw841 (2017). 292 17 Lloyd-Smith, J. O., Schreiber, S. J., Kopp, P. E. & Getz, W. M. Superspreading and the 293 effect of individual variation on disease emergence. *Nature* **438**, 355-359, 294 doi:10.1038/nature04153 (2005).

Chu, D. K. et al. Physical distancing, face masks, and eye protection to prevent person-to-

person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-

analysis. Lancet 395, 1973-1987, doi:10.1016/S0140-6736(20)31142-9 (2020).

295


296

297

18

298 19 Yu, I. T. et al. Evidence of airborne transmission of the severe acute respiratory syndrome 299 virus. N. Engl. J. Med. 350, 1731-1739, doi:10.1056/NEJMoa032867 (2004). 300 20 Cowling, B. J. et al. Aerosol transmission is an important mode of influenza A virus 301 spread. Nat. Commun. 4, 1935, doi:10.1038/ncomms2922 (2013). 302 21 Pitzer, V. E., Leung, G. M. & Lipsitch, M. Estimating variability in the transmission of 303 severe acute respiratory syndrome to household contacts in Hong Kong, China. Am. J. 304 Epidemiol. 166, 355-363, doi:10.1093/aje/kwm082 (2007). 305 22 Roberts, M. G. & Nishiura, H. Early estimation of the reproduction number in the presence 306 of imported cases: pandemic influenza H1N1-2009 in New Zealand. PLoS One 6, e17835, 307 doi:10.1371/journal.pone.0017835 (2011). 308 23 Brugger, J. & Althaus, C. L. Transmission of and susceptibility to seasonal influenza in 309 Switzerland from 2003 to 2015. *Epidemics* **30**, 100373, doi:10.1016/j.epidem.2019.100373 310 (2020).311 24 Ma, J. et al. COVID-19 patients in earlier stages exhaled millions of SARS-CoV-2 per 312 hour. Clin. Infect. Dis., doi:10.1093/cid/ciaa1283 (2020). 313 25 Cheng, H. Y. et al. Contact tracing assessment of COVID-19 transmission dynamics in 314 Taiwan and risk at different exposure periods before and after symptom onset. JAMA 315 Intern. Med., doi:10.1001/jamainternmed.2020.2020 (2020). 316 26 Wei, W. E. et al. Presymptomatic transmission of SARS-CoV-2 — Singapore, January 23-317 March 16, 2020. MMWR Morb. Mortal. Wkly. Rep. 69, 411-415, 318 doi:10.15585/mmwr.mm6914e1 (2020). 319 27 Du, Z. et al. Serial interval of COVID-19 among publicly reported confirmed cases. 320 Emerg. Infect. Dis. 26, 1341-1343, doi:10.3201/eid2606.200357 (2020).

321	28	Abkarian, M., Mendez, S., Xue, N., Yang, F. & Stone, H. A. Speech can produce jet-like
322		transport relevant to asymptomatic spreading of virus. Proc. Natl. Acad. Sci. U. S. A.,
323		doi:10.1073/pnas.2012156117 (2020).
324	29	Bourouiba, L. Turbulent gas clouds and respiratory pathogen emissions: potential
325		implications for reducing transmission of COVID-19. JAMA 323, 1837-1838,
326		doi:10.1001/jama.2020.4756 (2020).
327	30	Guan, W. J. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J.
328		Med. 382, 1708-1720, doi:10.1056/NEJMoa2002032 (2020).
329	31	Luo, L. et al. Contact settings and risk for transmission in 3410 close contacts of patients
330		with COVID-19 in Guangzhou, China: a prospective cohort study. Ann. Intern. Med.,
331		doi:10.7326/M20-2671 (2020).
332	32	Lu, X. et al. SARS-CoV-2 infection in children. N. Engl. J. Med. 382, 1663-1665,
333		doi:10.1056/NEJMc2005073 (2020).
334	33	CDC COVID-19 Response Team. Coronavirus disease 2019 in children - United States,
335		February 12-April 2, 2020. MMWR Morb. Mortal. Wkly. Rep. 69, 422-426,
336		doi:10.15585/mmwr.mm6914e4 (2020).
337	34	Han, M. S., Byun, J. H., Cho, Y. & Rim, J. H. RT-PCR for SARS-CoV-2: quantitative
338		versus qualitative. Lancet Infect. Dis., doi:10.1016/S1473-3099(20)30424-2 (2020).
339	35	van Kampen, J. J. A. et al. Shedding of infectious virus in hospitalized patients with
340		coronavirus disease-2019 (COVID-19): duration and key determinants. Preprint at
341		medRxiv doi:10.1101/2020.06.08.20125310 (2020).



343 Fig. 1. Development of the systematic dataset.




Fig. 2. Subgroup analyses of SARS-CoV-2 respiratory viral load during the infectious period. Random-effects meta-analyses comparing the expected rVLs of adult (>18 years old) COVID-19 cases with pediatric ( $\leq$ 18 years old) ones (top) and symptomatic/presymptomatic infections with asymptomatic ones (bottom) during the infectious period. Quantitative specimen measurements were used to estimate rVLs, which refer to virus concentrations in the respiratory tract. Case types: hospitalized (H), not admitted (N), community (C), adult (A), pediatric (P), symptomatic (S), presymptomatic (Ps) and asymptomatic (As). Specimen types: endotracheal aspirate (ETA), nasopharyngeal aspirate (NPA), nasopharyngeal swab (NPS), oropharyngeal swab (OPS), posterior oropharyngeal saliva (POS) and sputum (Spu). Studies after ref. 35 are listed in Methods. Dashes denote case numbers that were not obtained. Box sizes are proportional to weighting in the overall estimates. Two-sided Welch's *t*-tests, non-significance (p>0.05).





Fig. 3. Heterogeneity and kinetics of SARS-CoV-2 respiratory viral load. a, Estimated distribution of rVL for SARS-CoV-2 (n=3,778 samples from n=24 studies) and A(H1N1)pdm09 (n=512 samples from n=10 studies) throughout the infectious periods. b, Meta-regression of dispersion parameter (k) with the standard deviation (SD) of rVLs from included studies (r=-0.27). Estimates of k were pooled from the literature. Red, yellow and blue circles denote COVID-19 (n=27), SARS (n=9) and A(H1N1)pdm09 (n=27) studies, respectively. Circle sizes are proportional to weighting in the meta-regression. The p-value was obtained using the meta-regression slope t-test. c, SARS-CoV-2 rVLs fitted to a mechanistic model of viral kinetics (black curve, r=0.88). Filled circles and bars depict mean estimates and 95% CIs. Open circles show the entirety of individual sample data over DFSO (left to right, n=3, 15, 48, 59, 69, 71, 81, 87, 102, 125, 119, 117 and 110 samples from n=19 studies). d, Estimated distributions of SARS-CoV-2 rVL over DFSO. Earlier DFSO were excluded based on limited data. Weibull distributions were fitted on the entirety of individual sample data for the virus (a) or DFSO (d) in the systematic dataset. Arrows denote 90th case percentiles for SARS-CoV-2 rVL.



**Fig. 4. Heterogeneity in shedding SARS-CoV-2 via droplets and aerosols. a,b**, Likelihood of respiratory particles containing viable SARS-CoV-2 when expelled by the mean (top) or 98<sup>th</sup> case percentile (cp) (bottom) COVID-19 cases at -1 (a) or 1 (b) DFSO. The models considered virus viability within dehydrated particles. Diameters during atomization were included to show

their size relationship with dehydrated aerodynamic diameter ( $d_a$ ), but not likelihood of containing virions during atomization. For higher no. of virions, some likelihood curves were omitted to aid visualization. When the likelihood for 0 virions approaches 0%, particles are expected to contain at least one viable copy. **c-f**, Rate that the mean and 98<sup>th</sup>-cp COVID-19 cases at 1 DFSO shed viable SARS-CoV-2 by talking (**c**), singing (**d**), breathing (**e**) or coughing (**f**) over  $d_a$ . **g**, Relative contribution of aerosols ( $d_a \le 5 \mu m$ , red bar) and droplets ( $d_a > 5 \mu m$ , blue bar) to shedding virions for the respiratory activities. **h**, Case heterogeneity in the total shedding rate (over all particle sizes) of virions via singing across the infectious period. Earlier presymptomatic days were excluded based on limited data. Data range between the 1<sup>st</sup> and 99<sup>th</sup> cps. Lines and bands represent estimates and 95% CIs, respectively, for likelihoods or Poisson means.

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

Methods Search strategy, selection criteria and data collection We undertook a systematic review and prospectively submitted the systematic review protocol for registration on PROSPERO (registration number, CRD42020204637). Other than the title of this study, we have followed PRISMA reporting guidelines<sup>36</sup>. The systematic review was conducted according to Cochrane methods guidance<sup>37</sup>. The search included papers that (i) reported positive, quantitative measurements (copies/ml or an equivalent metric) of SARS-CoV-2, SARS-CoV-1 or A(H1N1)pdm09 in human respiratory specimens (ETA, NPA, NPS, OPS, POS and Spu) from COVID-19, SARS or A(H1N1)pdm09 cases; (ii) reported data that could be extracted from the infectious periods of SARS-CoV-2 (defined as -3 to +10 DFSO for symptomatic cases and 0 to +10 days from the day of laboratory diagnosis for asymptomatic cases), SARS-CoV-1 (defined as 0 to +20 DFSO or the equivalent asymptomatic period) or A(H1N1)pdm09 (defined as -2 to +9 DFSO for symptomatic cases and 0 days to +9 days from the day of laboratory diagnosis for asymptomatic cases); and (iii) reported data for two or more cases with laboratory-confirmed COVID-19, SARS or A(H1N1)pdm09. Quantitative specimen measurements were considered after RNA extraction for diagnostic sequences of SARS-CoV-2 (Ofr1b, N, RdRp and E genes), SARS-CoV-1 (Ofr1b, N and RdRp genes) and A(H1N1)pdm09 (HA and M genes). Studies were excluded, in the following order, if they (i) studied an ineligible disease; (ii) had an ineligible study design, including those that were reviews of evidence (e.g., scoping, systematic, narrative), did not include primary clinical human data, reported data for less than two cases due to an increased risk of selection bias, were incomplete (e.g., ongoing clinical

trials), did not report an RNA extraction step before measurement or were studies measuring

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

environmental samples; (iii) reported an ineligible metric for specimen concentration (e.g., qualitative RT-PCR or cycle threshold [Ct] values without calibration included in the study); (iv) reported quantitative measurements from an ineligible specimen type (e.g., blood specimens, pooled specimens or self-collected POS or Spu patient specimens in the absence of a healthcare professional); (v) reported an ineligible sampling period (consisted entirely of data that could not be extracted from within the infectious period); or (vi) were duplicates of an included study (e.g., preprinted version of published paper or duplicates not identified by Covidence). We included data from control groups receiving standard of care in interventional studies but excluded data from the intervention group. Patients in the intervention group are, by definition, systematically different from general case populations because they receive therapies not being widely used for treatment, which may influence virus concentrations. Interventional studies examining the comparative effectiveness of two or more treatments were excluded for the same reason. Studies exclusively reporting semiquantitative measurements (e.g., Ct values) of specimen concentration were excluded, as these measurements are sensitive to batch inconsistencies and, without proper calibration, cannot be compared on an absolute scale across studies<sup>34</sup>. We searched, without the use of filters or language restrictions, the following sources: MEDLINE (via Ovid, 1946 to 7 August 2020), EMBASE (via Ovid, 1974 to 7 August 2020, Cochrane Central Register of Controlled Trials (via Ovid, 1991 to 7 August 2020), Web of Science Core Collection (including: Science Citation Index Expanded, 1900 to 7 August 2020; Social Sciences Citation Index, 1900 to 7 August 2020; Arts & Humanities Citation Index, 1975 to 7 August 2020; Conference Proceedings Citation Index - Science, 1990 to 7 August 2020; Conference Proceedings Citation Index - Social Sciences & Humanities, 1990 to 7 August 2020; and Emerging Sources Citation Index, 2015 to 7 August 2020), as well as MedRxiv and BioRxiv

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

451

452

453

454

455

(both searched through Google Scholar via the Publish or Perish program, to 7 August 2020). We also gathered studies by searching through the reference lists of review articles identified by the database search, by searching through the reference lists of included articles, through expert recommendation (by Epic J. Topol, Akiko Iwasaki and A. Marm Kilpatrick on Twitter) and by hand-searching through journals (Nature, Nat. Med., Science, NEJM, Lancet, Lancet Infect. Dis., JAMA, JAMA Intern. Med. and BMJ). A comprehensive search was developed by a librarian, which included subject headings and keywords. The search strategy had 3 main concepts (disease, specimen type and outcome), and each concept was combined using the appropriate Boolean operators. The search was tested against a sample set of known articles that were preidentified. The line-by-line search strategies for all databases are included in Supplementary Tables 1-5. The search results were exported from each database and uploaded to the Covidence online system for deduplication and screening. Two authors independently screened titles and abstracts, reviewed full texts, collected data and assessed risk of bias via Covidence and a hybrid critical appraisal checklist based on the Joanna Briggs Institute (JBI) tools for case series, analytical cross-sectional studies and prevalence studies<sup>38-40</sup>. To evaluate the sample size in a study, we used the following calculation:

$$n^* = \frac{z^2 \sigma}{d^2},\tag{1}$$

where  $n^*$  is the sample size threshold, z is the z-score for the level of confidence (95%),  $\sigma$  is the standard deviation (assumed to be  $3 \log_{10} \text{ copies/ml}$ , one quarter of the full range of rVLs) and d is the marginal error (assumed to be  $1 \log_{10} \text{ copies/ml}$ , based on the minimum detection limit for qRT-PCR across studies)<sup>41</sup>. The hybrid JBI critical appraisal checklist is shown in the Supplementary Notes. Inconsistencies were resolved by discussion and consensus.

The search found 27 studies for COVID-19<sup>13,35,42-66</sup>, 9 studies for SARS<sup>67-75</sup> and 27 studies for A(H1N1)pdm09<sup>76-102</sup>. Quantitative specimen measurements were collected directly if reported numerically or using WebPlotDigitizer 4.3 (https://apps.automeris.io/wpd/) if reported graphically. For included studies, we also collected the relevant numbers of cases, types of cases, volumes of transport media, pharmacotherapies, DFSO (for symptomatic cases) or day relative to initial laboratory diagnosis (for asymptomatic cases) on which each specimen was taken and numbers of tested specimens. Hospitalized cases were defined as those being tested in a hospital setting and then admitted. Non-admitted cases were defined as those being tested in a community setting but not admitted. Community cases were defined as those being tested in a community setting. Symptomatic, presymptomatic and asymptomatic infections were defined as in the study. Based on rare description in the included studies, paucisymptomatic infections, when defined in a study, were included with symptomatic ones. Pediatric cases were defined as those above 18 years of age or lower or as defined in the study. Adult cases were defined as those above 18 years of age or as defined in the study.

#### Meta-analysis of rVLs

Based on the search design and composition of included studies, the meta-analysis overall estimates were the expected SARS-CoV-2, SARS-CoV-1 and A(H1N1)pdm09 rVL when encountering a COVID-19, SARS or A(H1N1)pdm09 case, respectively, during their infectious period. To determine rVLs, data collected on positive, quantitative specimen measurements were converted to the RNA concentration in the respiratory tract. Viral concentrations in respiratory specimens were denoted as specimen measurements, whereas viral concentrations in the respiratory tract were denoted as rVLs. For example, measurements from swabbed specimens

(NPS and OPS) typically report the RNA concentration in viral transport media. Based on the expected uptake volume for swabs  $(0.128 \pm 0.031 \text{ ml}, \text{mean} \pm \text{SD})^{103}$  or reported collection volume for expulsed fluid in each study (e.g., 0.5 to 1 ml) along with the reported volume of transport media in each study (e.g., 1 ml), we calculated the dilution factor for each respiratory specimen to estimate the rVLs. If the diluent volume was not reported, then the dilution factor was calculated assuming a volume of 1 ml (NPS and OPS), 2 ml (POS and ETA) or 3 ml (NPA) of transport media<sup>43,45,71</sup>. Unless dilution was reported for Spu specimens, we used the specimen measurement as the rVL<sup>13</sup>. The non-reporting of diluent volume was noted as an element increasing risk of bias in the hybrid JBI critical appraisal checklist. Viral load estimates (based on instrumentation, calibration, procedures and reagents) are not standardized. While the above procedures (including only quantitative measurements after extraction, collecting assay detection limits, correcting for specimen dilution) have considered many of these factors, nonstandardization is an inherent limitation in interpreting specimen measurements across studies. Pooled estimates and 95% CIs for the expected rVL of each virus across their infectious period were calculated using a random-effects meta-analysis. The estimates for rVL assumed that each viral copy was extracted and quantified from the tested specimen aliquot. For studies reporting summary statistics in medians and interquartile or total ranges, we derived estimates of the mean and variance and calculated the 95% CIs<sup>104</sup>. All calculations were performed in units of  $log_{10}$  copies/ml. Between-study heterogeneity in meta-analysis was assessed using the  $I^2$  and  $\tau^2$ statistics. The weighting for each study in its virus group was calculated as the reciprocal of the rVL variance.

## Subgroup analyses of rVLs

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

Subgroup analyses were conducted to compare the expected rVLs of SARS-CoV-2 in adult, pediatric, symptomatic and asymptomatic COVID-19 cases, as previously defined, during the infectious period. The overall estimate for each subgroup was the expected rVL when encountering a case of that subgroup during the infectious period. Studies reporting data exclusively from a subgroup of interest were included in the analysis without modification. For studies in which data for these subgroups constituted only part of its dataset, rVLs from the subgroup were collected to calculate the mean, variance and 95% CIs. All calculations were performed in units of  $log_{10}$  copies/ml. In the analysis, we excluded studies with only a single case in our subgroups of interest. Pooled estimates and 95% CIs for each subgroup were calculated using a random-effects meta-analysis, in which between-study heterogeneity was assessed using the  $\ell^2$  and  $\tau^2$  statistics. The weighting for each study in its subgroup was calculated as the reciprocal of the rVL variance.

## Distribution of rVL

To analyze heterogeneity in rVLs, we pooled the entirety of individual sample data (reported as individual specimen measurements rather through descriptive statistics) in the systematic dataset by disease, COVID-19 subgroups and DFSO. For analyses of SARS-CoV-2 dynamics across DFSO, we included estimated rVLs from negative qRT-PCR measurements of respiratory specimens (n=3, 3, 6, 8, 12, 15, 13, 17 and 14 negative specimens for 2, 3, 4, 5, 6, 7, 8, 9 and 10 DFSO, respectively) for cases that had previously been quantitatively confirmed to have COVID-19. These rVLs were estimated based on the reported assay detection limit in the respective study. Probability plots and modified Kolmogorov–Smirnov tests were used to determine the suitability of normal, lognormal, gamma and Weibull distributions to describe the

distribution of rVLs for SARS-CoV-2, SARS-CoV-1 and A(H1N1)pdm09. For each virus, the

data best conformed to Weibull distributions, which is described by the probability density

527 function

526

530

$$f(v) = \frac{\alpha}{\beta} \left(\frac{v}{\beta}\right)^{\alpha - 1} e^{-(v/\beta)^{\alpha}},\tag{2}$$

where  $\alpha$  is the shape factor,  $\beta$  is the scale factor and  $\nu$  is rVL ( $\nu \ge 0 \log_{10} \text{ copies/ml}$ ). In this

distribution, the value of the rVL at the  $x^{th}$  percentile was determined using the quantile function,

$$v_x = \beta [-\ln(1-x)]^{1/\alpha}. \tag{3}$$

- For cp curves, we used eq. (3) to determine rVLs from the 1st cp to the 99th cp (step size, 1%).
- 533 Curve fitting to eq. (2) and calculation of eq. (3) and its 95% CI was performed using the
- Distribution Fitter application in Matlab R2019b (MathWorks, Inc., Natick, Massachusetts,
- 535 USA).

536

539

540

541

542

543

544

545

546

547

## Meta-regression of k and heterogeneity in rVL

To assess the relationship between k and heterogeneity in rVL, we performed a univariate meta-

regression (log k = a(SD) + b, where a is the slope for association and b is the intercept)

between pooled estimates of k (based on studies describing community transmission) for

COVID-19  $(k=0.409)^{4-6,105-108}$ , SARS  $(k=0.165)^{17}$  and A(H1N1)pdm09  $(k=8.155)^{22,23}$  and the SD

of the rVLs in each study. Since the negative binomial distribution, from which k is derived  $^{17}$ , is

analogous to a compound Poisson distribution in which each random variable is Log(k)-

distributed, the meta-regression was performed with log k. Based on negligible between-study

heterogeneity, we used a fixed-effects model. This analysis assumes that the SD of rVLs in each

study estimates SD of rVL for the disease. Thus, for weighting in the meta-regression, we used

the proportion of rVL samples for each study relative to the entire systematic dataset ( $W_i$  =

 $n_i/n_{\text{total}}$ ). The regression line, its 95% CI and its Pearson correlation coefficient (r) were presented along with the p-value for association (meta-regression slope t-test for a) between the two variables. The meta-regression assumed that the viability proportion (for viruses exiting the respiratory tract) was similar across cases for a given respiratory infection; it could be a different value for different diseases. The meta-regression also assumed that the rate profile of particles expelled by respiratory activities (e.g., talking) is similar among the diseases. The limit of detection for qRT-PCR instruments used in the included studies did not significantly affect the analysis of heterogeneity in rVL, as these limits tended to be below the values found for specimens with low virus concentrations.

# Viral kinetics

- To model the kinetics of SARS-CoV-2 rVL, we used a mechanistic epithelial cell-limited model
- for the respiratory tract<sup>109</sup>, based on the system of differential equations:

$$\frac{dT}{dt} = -\beta TV \tag{4}$$

$$\frac{dI}{dt} = \beta TV - \delta I \tag{5}$$

$$\frac{dV}{dt} = pI - cV,\tag{6}$$

where T is the number of uninfected target cells, I is the number of productively infected cells, V is the rVL,  $\beta$  is the infection rate constant, p is the rate at which airway epithelial cells shed virus to the extracellular fluid, c is the clearance rate of the virus and  $\delta$  is the clearance rate of productively infected cells. Parameter units are summarized in Extended Data Table 3. Using these parameters, the viral half-life in the respiratory tract ( $t_{1/2} = \ln 2/c$ ) and the half-life of productively infected cells ( $t_{1/2} = \ln 2/\delta$ ) and their 95% CIs could be estimated. Moreover, the

cellular basic reproductive number (the expected number of secondary infected cells from a single productively infected cell placed in a population of susceptible cells) was calculated by

$$R_{0,c} = \frac{p\beta T_0}{c\delta},\tag{7}$$

- 573 where  $T_0$  is the initial number of susceptible cells<sup>109</sup>.
- For initial parameterization, eqs. (4)-(6) were simplified according to a quasi-steady state
- 575 approximation<sup>110</sup> to

$$\frac{dT}{dt} = -\beta TV \tag{8}$$

$$\frac{dV}{dt} = rTV - \delta V,\tag{9}$$

where  $r=p\beta/c$ , for a form with greater numerical stability. The system of differential equations was fitted on the mean estimates of SARS-CoV-2 rVL between -2 and 10 DFSO using the entirety of individual sample data in units of copies/ml. Numerical analysis was implemented using the Fit ODE app in OriginPro 2019b (OriginLab Corporation, Northampton, Massachusetts, USA) via the Runge-Kutta method and initial parameters  $V_0$ ,  $I_0$  and  $T_0$  of 4 copies/ml, 0 cells and  $5\times10^7$  cells, respectively, for the range -5 to 10 DFSO. The analysis was first performed with eqs. (8)-(9). These output parameters were then used to initialize final analysis using eqs. (4)-(6), where the estimates for  $\beta$  and  $\delta$  were input as fixed and variable parameters, respectively. The fitted line and its coefficient of determination ( $r^2$ ) were presented.

To estimate the average incubation period, we extrapolated the kinetic model to 0 and 1 log<sub>10</sub> copies/ml pre-symptom onset. To estimate the average duration of shedding, we extrapolated the model to 0 log<sub>10</sub> copies/ml post-symptom onset. Unlike experimental estimates, this estimate for duration of shedding was not defined by assay detection limits. These analyses had limitations. To estimate the average DFSO on which SARS-CoV-2 concentration reached

diagnostic levels, we extrapolated the model pre-symptom onset to the equivalent of 1 and 3 log<sub>10</sub> copies/ml in specimen concentration (chosen as example assay detection limits), as described by the dilution factor estimation above. The average time from respiratory infection to reach diagnostic levels was then calculated by subtracting these values from the incubation period for 0 log<sub>10</sub> copies/ml. However, the extrapolated time for SARS-CoV-2 to reach diagnostic concentrations in the respiratory tract should be validated in tracing studies, in which contacts are prospectively subjected to daily sampling.

#### Considerations for particle dehydration

The desiccation time of a particle in air was described  $t_{des} = b^{-1}(d_i^2 - d_{des}^2)$ , where b is prefactor for dehydration rate which depends on the environmental conditions,  $d_i$  is the initial hydrated diameter and  $d_{des}$  is particle diameter after desiccation<sup>111</sup>. After desiccation, the remaining non-volatile matter (ions, molecules, viruses and cells) governs particle size, which is approximately 0.44 times the initial size of particles atomized in the respiratory tract<sup>112</sup>. Dehydrated aerodynamic diameter was calculated by  $d_a = d_p(\rho/\rho_0)^{1/2}$ , where  $d_p$  is the dehydrated particle size,  $\rho$  is the material density of the respiratory particle and  $\rho_0$  is the reference material density (1 g/cm<sup>3</sup>). For conservative estimates, the value of b was taken to be 64.9  $\mu$ m<sup>2</sup>/s<sup>113</sup> based on conditions of room temperature and a relative humidity of 59% (near the upper limit of 60% for healthcare and typical indoor specifications)<sup>114</sup>. The equation for desiccation time indicated that respiratory particles begin to dehydrate immediately upon release to the ambient environment. Desiccation occurred rapidly, as the equation estimated that an 11.4- $\mu$ m particle desiccated to 5  $\mu$ m in 1.6 s within the model conditions, and this value was an upper limit for the desiccation times of aerosols ( $t_{des} \le 1.6$  s).

# Likelihood of respiratory particles containing virions

To calculate an unbiased estimator for viral partitioning (the expected number of viable copies in an expelled particle at a given size), we multiplied rVLs with the volume equation for spherical particles during atomization and the estimated viability proportion:

$$\lambda = \frac{\pi \rho v_p \gamma v}{6} d^3, \tag{10}$$

where  $\lambda$  is the expectation value,  $\rho$  is the material density of the respiratory particle (997 g/m³),  $v_p$  is the volumetric conversion factor (1 ml/g),  $\gamma$  is the viability proportion, v is the rVL and d is the hydrated diameter of the particle during atomization. The model assumed  $\gamma$  was 0.1% for the viruses. For influenza, approximately 0.1% of copies in particles expelled from the respiratory tract represent viable virus<sup>115</sup>, which is equivalent to one in 3 log<sub>10</sub> copies/ml for rVL or, after dilution in transport media, roughly one in 4 log<sub>10</sub> copies/ml for specimen concentration. Recent reports have detected culture-positive respiratory specimens with SARS-CoV-2 concentrations down to 4 log<sub>10</sub> copies/ml<sup>13</sup>, including from pediatric patients<sup>62</sup> and in the presymptomatic period<sup>15</sup>, suggesting the assumption was also suitable for SARS-CoV-2.

Likelihood profiles were determined using Poisson statistics, as described by the probability mass function

632 
$$P(X = k) = \frac{\lambda^k e^{-\lambda}}{k!},$$
 (11)

where k is the number of virions partitioned within the particle. For  $\lambda$ , 95% CIs were determined using the variance of its rVL estimate. To determine 95% CIs for likelihood profiles from the probability mass function, we used the delta method, which specifies

636 
$$\operatorname{Var}(g(\boldsymbol{\theta})) \approx \sigma^2 \dot{g}(\boldsymbol{\theta})' \mathbf{D} \dot{g}(\boldsymbol{\theta}), \tag{12}$$

where  $\sigma^2 \mathbf{D}$  is the covariance matrix of  $\boldsymbol{\theta}$  and  $\dot{g}(\boldsymbol{\theta})$  is the gradient of  $g(\boldsymbol{\theta})$ . For the univariate

Poisson distribution,  $\sigma^2 \mathbf{D} = \lambda$  and

$$\dot{g}(\theta) = \frac{\lambda^{k-1} e^{-\lambda}}{k!} (k - \lambda). \tag{13}$$

Based on the relative relationship between the residence time of expelled particles before assessment (~5 s)<sup>116</sup> in the referenced study<sup>115</sup> and the estimated dehydration rates of expelled particles, we took the viability proportion (0.1%) to be for dehydrated particles. The model calculated partitioning of copies using the hydrated volume and then applied the viability proportion for number of virions in particles after emission and dehydration. Thus, we compared likelihoods among expelled, dehydrated particles. In Fig. 4, the comparison between hydrated and dehydrated diameters showed only the relationship in particle size and not the relationship in likelihood of containing viable virus. Based on the scope of the study, the model did not account for the virion half-life as particles deposit onto surfaces or remain suspended in air<sup>117</sup>.

#### Rate profiles of particles expelled by respiratory activities

For the rate profiles of particles expelled during respiratory activities, we used distributions from the literature. For coughing, we considered the rate (particles/cough) of expelling particles at different sizes, as determined by Loudon and Roberts<sup>118</sup>, by calculating the mean number of respiratory particles expelled per cough based on subject tests RI, RII, LI, LII and EI (EII was presumed to be an outlier based on the relative rate when compared to EI). These particles were taken to be dehydrated based on the deposition time in the experiment relative to estimated dehydration rates. We compared this rate profile to that of Duguid<sup>119</sup>, which were taken to be hydrated particles based on experimental design. For talking, singing and breathing, we obtained data from Morawaska et al<sup>120</sup>. Rate profiles (particles/min) were calculated by converting the

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

normalized concentration (particles/cm<sup>3</sup>) at each particle size based on normalization (32 channels per decade) for the aerodynamic particle sizer (APS) used, unit conversion (cm<sup>3</sup> to L) and the sample flow rate (1 L/min). Rate profiles of talking and singing were isolated from breathing by subtracting the contribution of breathing to the combined data. Particles were taken to be dehydrated based on the minimum particle age in the measurements. Based on the APS used, the analyzed range for  $d_a$  was 0.3-20 µm. While larger droplets may potentially be expelled by the respiratory activities, the data suggested that their emission rates were minimal, and there was a limited bias associated with instrumentation. We compared these data for talking with rate profiles of talking loudly and talking quietly from Asadi et al<sup>121</sup>. For data reported in a size channel, we took the particle size to be the median value. Curves based on discrete particle measurements were connected using the nonparametric Akima spline function. Shedding virions via respiratory droplets and aerosols To determine the respiratory shedding rate across particle size, rVL estimates and the hydrated diameters of particles expelled by a respiratory activity were input into eq. (10), and the output was then multiplied by the rate profile of the activity (talking, singing, breathing or coughing). Dehydration and viability considerations were continued from the likelihood models. The model used particle profiles from (coughing) Loudon and Roberts<sup>118</sup> or (talking, singing and breathing) Morawaska et al<sup>120</sup>. To determine the total respiratory shedding rate for a given respiratory activity across cp, we determined the cumulative hydrated volumetric rate (by summing the hydrated volumetric rates across particle sizes for that respiratory activity) and input it into eq. (10). Using rVLs as

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

determined by the Weibull quantile functions, we then calculated the Poisson means and their 95% CIs at different cps. To assess the relative contribution of aerosols and droplets to mediating respiratory viral shedding for a given respiratory activity, we calculated the proportion of the cumulative hydrated volumetric rate contributed by aerosols ( $d_a \le 5 \mu m$ ) or droplets ( $d_a > 5 \mu m$ ) for that respiratory activity. Since the Poisson mean was proportional to cumulative volumetric rate, this estimate of the relative contribution of aerosols and droplets to respiratory viral shedding was consistent among viruses and cps in the model. In this study, the model for shedding virions via droplets and aerosols did not delineate particles generated in the upper respiratory tract from those generated in the lower respiratory tract, as the sites of atomization remain poorly understood. It also did not differentiate cases with significant expectoration from those without it. In addition, it did not account for individual variation in the profiles of expelled particles; superemitters can expel respiratory particles at rates  $\sim$ 3 times above median<sup>121</sup>. Statistical analysis For data collection, statistical analysis, coding and data visualization, we used Excel v16.40 (Microsoft Corporation, Redmond, Washington, USA), OriginPro 2019b (OriginLab Corporation, Northampton, Massachusetts, USA) and Matlab R2019b (MathWorks, Inc., Natick, Massachusetts, USA). Between-study heterogeneity in the random-effects meta-analyses was assessed using the  $I^2$  and  $\tau^2$  statistics. Probability plots for normal, lognormal, gamma and Weibull distributions of rVLs were scored based on the Blom method. Modified Kolmogorov-Smirnov tests were used to determine the goodness of fits between rVLs (in log<sub>10</sub> copies/ml) and

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

normal, lognormal, gamma or Weibull distributions. By accepting the null hypothesis in the modified Kolmogorov-Smirnov test, the given distribution cannot be rejected to fit the data. Based on fitted Weibull distribution parameters, the Weibull quantile function was used to determine the rVL and its 95% CIs at a given cp. The association between k and rVL was assessed via meta-regression, and the p-value for association was based on the meta-regression slope t-test. Likelihood profiles were determined using the Poisson probability mass function and the unbiased estimator for the expected partitioning of virions at a given particle size. Variance on likelihood estimates was determined via the delta method. Since case variance or sample size may be unequal among the viral infections or subgroups, the two-sided Welch's t-test was used to compare the difference of expected rVLs in the meta-analysis and subgroup analyses. For all statistical analyses, the significance level ( $\alpha$ ) was taken to be 0.05. Data availability Data will be made available upon request. All raw data, code and model outputs from this study will be made publicly available in online repositories after peer review. Search strategies for the systematic review are shown in Supplementary Tables 1-5. The systematic review protocol was prospectively registered on PROSPERO (registration number, CRD42020204637). **References (for Methods)** 36 Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. & Group, P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* 6,

e1000097, doi:10.1371/journal.pmed.1000097 (2009).

- 727 37 Higgins, J. P. T. et al. Cochrane Handbook for Systematic Reviews of Interventions. (John
- 728 Wiley & Sons, 2019).
- 729 38 Munn, Z. et al. Methodological quality of case series studies: an introduction to the JBI
- critical appraisal tool. JBI Database System Rev Implement Rep, doi:10.11124/JBISRIR-D-
- 731 19-00099 (2019).
- 732 39 Moola, S. et al. Chapter 7: Systematic reviews of etiology and risk. JBI Manual for
- 733 Evidence Synthesis. (The Joanna Briggs Institute, 2020).
- 734 40 Munn, Z., Moola, S., Lisy, K., Riitano, D. & Tufanaru, C. Methodological guidance for
- systematic reviews of observational epidemiological studies reporting prevalence and
- cumulative incidence data. *Int. J. Evid. Based Healthc.* **13**, 147-153,
- 737 doi:10.1097/XEB.000000000000054 (2015).
- 738 41 Johnston, K. M., Lakzadeh, P., Donato, B. M. K. & Szabo, S. M. Methods of sample size
- calculation in descriptive retrospective burden of illness studies. BMC Med. Res. Methodol.
- 740 **19**, 9, doi:10.1186/s12874-018-0657-9 (2019).
- 741 42 Zhang, N. et al. Comparative study on virus shedding patterns in nasopharyngeal and fecal
- 742 specimens of COVID-19 patients. Sci China Life Sci, doi:10.1007/s11427-020-1783-9
- 743 (2020).
- Lavezzo, E. et al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of
- 745 Vo'. *Nature* **584**, 425-429, doi:10.1038/s41586-020-2488-1 (2020).
- Peng, L. et al. SARS-CoV-2 can be detected in urine, blood, anal swabs, and
- 747 oropharyngeal swabs specimens. J. Med. Virol., doi:10.1002/jmv.25936 (2020).

748 45 To, K. K. et al. Temporal profiles of viral load in posterior or pharyngeal saliva samples 749 and serum antibody responses during infection by SARS-CoV-2: an observational cohort 750 study. Lancet Infect. Dis. 20, 565-574, doi:10.1016/S1473-3099(20)30196-1 (2020). 751 46 Zou, L. et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. 752 N. Engl. J. Med. 382, 1177-1179, doi:10.1056/NEJMc2001737 (2020). 753 47 Fainzylber, J. M. et al. SARS-CoV-2 viral load is associated with increased disease 754 severity and mortality. Preprinted at medRxiv, doi:10.1101/2020.07.15.20131789 (2020). 755 48 Zheng, S. et al. Viral load dynamics and disease severity in patients infected with SARS-756 CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. BMJ 757 **369**, m1443, doi:10.1136/bmj.m1443 (2020). 758 49 Lennon, N. J. et al. Comparison of viral levels in individuals with or without symptoms at 759 time of COVID-19 testing among 32,480 residents and staff of nursing homes and assisted 760 living facilities in Massachusetts. Preprinted at medRxiv, 761 doi:10.1101/2020.07.20.20157792 (2020). 762 50 Shrestha, N. K. et al. Distribution of transmission potential during nonsevere COVID-19 763 illness. Clin. Infect. Dis., doi:10.1093/cid/ciaa886 (2020). 764 51 Shi, F. et al. Association of viral load with serum biomakers among COVID-19 cases. 765 Virology **546**, 122-126, doi:10.1016/j.virol.2020.04.011 (2020). 766 52 Hung, I. F. et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin 767 in the treatment of patients admitted to hospital with COVID-19: an open-label, 768 randomised, phase 2 trial. Lancet 395, 1695-1704, doi:10.1016/S0140-6736(20)31042-4

769

(2020).

- 770 53 Iwasaki, S. et al. Comparison of SARS-CoV-2 detection in nasopharyngeal swab and
- 771 saliva. *J. Infect.* **81**, e145-e147, doi:10.1016/j.jinf.2020.05.071 (2020).
- Perera, R. A. P. M. et al. SARS-CoV-2 virus culture from the upper respiratory tract:
- Correlation with viral load, subgenomic viral RNA and duration of illness. Preprinted at
- 774 medRxiv, doi:10.1101/2020.07.08.20148783 (2020).
- 775 55 Baggio, S. et al. SARS-CoV-2 viral load in the upper respiratory tract of children and
- adults with early acute COVID-19. Clin. Infect. Dis., doi:10.1093/cid/ciaa1157 (2020).
- 777 56 Lucas, C. et al. Longitudinal analyses reveal immunological misfiring in severe COVID-
- 778 19. *Nature* **584**, 463-469, doi:10.1038/s41586-020-2588-y (2020).
- 779 57 Argyropoulos, K. V. et al. Association of initial viral load in severe acute respiratory
- syndrome coronavirus 2 (SARS-CoV-2) patients with outcome and symptoms. Am. J.
- 781 *Pathol.* **190**, 1881-1887, doi:10.1016/j.ajpath.2020.07.001 (2020).
- 782 58 Mitja, O. et al. Hydroxychloroquine for early treatment of adults with mild Covid-19: a
- randomized-controlled trial. Clin. Infect. Dis., doi:10.1093/cid/ciaa1009 (2020).
- Vetter, P. et al. Daily viral kinetics and innate and adaptive immune responses assessment
- 785 in COVID-19: a case series. Preprinted at medRxiv, doi:10.1101/2020.07.02.20143271
- 786 (2020).
- 787 60 Xu, Y. et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for
- 788 persistent fecal viral shedding. *Nat. Med.* **26**, 502-505, doi:10.1038/s41591-020-0817-4
- 789 (2020).
- Hurst, J. H. et al. SARS-CoV-2 infections among children in the biospecimens from
- respiratory virus-exposed kids (BRAVE Kids) Study. Preprinted at medRxiv,
- 792 doi:10.1101/2020.08.18.20166835 (2020).

- 793 62 L'Huillier, A. G., Torriani, G., Pigny, F., Kaiser, L. & Eckerle, I. Culture-competent
- SARS-CoV-2 in nasopharynx of symptomatic neonates, children, and adolescents. *Emerg.*
- 795 *Infect. Dis.* **26**, 2494-2497, doi:10.3201/eid2610.202403 (2020).
- Han, M. S. et al. Viral RNA load in mildly symptomatic and asymptomatic children with
- 797 COVID-19, Seoul, South Korea. *Emerg. Infect. Dis.* **26**, 2497-2499,
- 798 doi:10.3201/eid2610.202449 (2020).
- 799 64 Pan, Y., Zhang, D., Yang, P., Poon, L. L. M. & Wang, Q. Viral load of SARS-CoV-2 in
- 800 clinical samples. *Lancet Infect. Dis.* **20**, 411-412, doi:10.1016/S1473-3099(20)30113-4
- 801 (2020).
- Han, M. S. et al. Sequential analysis of viral load in a neonate and her mother infected with
- 803 SARS-CoV-2. Clin. Infect. Dis., doi:10.1093/cid/ciaa447 (2020).
- 804 66 Kawasuji, H. et al. Viral load dynamics in transmissible symptomatic patients with
- 805 COVID-19. Preprinted at medRxiv, doi:10.1101/2020.06.02.20120014 (2020).
- 806 67 Chu, C. M. et al. Initial viral load and the outcomes of SARS. CMAJ 171, 1349-1352,
- 807 doi:10.1503/cmaj.1040398 (2004).
- 808 Poon, L. L. et al. Early diagnosis of SARS coronavirus infection by real time RT-PCR. J.
- 809 *Clin. Virol.* **28**, 233-238, doi:10.1016/j.jcv.2003.08.004 (2003).
- 810 69 Chen, W. J. et al. Nasopharyngeal shedding of severe acute respiratory syndrome-
- associated coronavirus is associated with genetic polymorphisms. Clin. Infect. Dis. 42,
- 812 1561-1569, doi:10.1086/503843 (2006).
- 813 70 Chu, C. M. et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological
- and clinical findings. *Thorax* **59**, 252-256, doi:10.1136/thorax.2003.012658 (2004).

815	71	Poon, L. L. et al. Detection of SARS coronavirus in patients with severe acute respiratory
816		syndrome by conventional and real-time quantitative reverse transcription-PCR assays.
817		Clin. Chem. 50, 67-72, doi:10.1373/clinchem.2003.023663 (2004).
818	72	Chu, C. M. et al. Viral load distribution in SARS outbreak. Emerg. Infect. Dis. 11, 1882-
819		1886, doi:10.3201/eid1112.040949 (2005).
820	73	Hung, I. F. et al. Viral loads in clinical specimens and SARS manifestations. Emerg. Infect.
821		Dis. 10, 1550-1557, doi:10.3201/eid1009.040058 (2004).
822	74	Cheng, V. C. et al. Viral replication in the nasopharynx is associated with diarrhea in
823		patients with severe acute respiratory syndrome. Clin. Infect. Dis. 38, 467-475,
824		doi:10.1086/382681 (2004).
825	75	Peiris, J. S. et al. Clinical progression and viral load in a community outbreak of
826		coronavirus-associated SARS pneumonia: a prospective study. Lancet 361, 1767-1772,
827		doi:10.1016/s0140-6736(03)13412-5 (2003).
828	76	Loeb, M. et al. Longitudinal study of influenza molecular viral shedding in Hutterite
829		communities. J. Infect. Dis. 206, 1078-1084, doi:10.1093/infdis/jis450 (2012).
830	77	Suess, T. et al. Shedding and transmission of novel influenza virus A/H1N1 infection in
831		householdsGermany, 2009. Am. J. Epidemiol. 171, 1157-1164, doi:10.1093/aje/kwq071
832		(2010).
833	78	Li, C. C. et al. Correlation of pandemic (H1N1) 2009 viral load with disease severity and
834		prolonged viral shedding in children. Emerg. Infect. Dis. 16, 1265-1272,
835		doi:10.3201/eid1608.091918 (2010).

836	79	Lu, P. X. et al. Relationship between respiratory viral load and lung lesion severity: a study
837		in 24 cases of pandemic H1N1 2009 influenza A pneumonia. J. Thorac. Dis. 4, 377-383,
838		doi:10.3978/j.issn.2072-1439.2012.08.02 (2012).
839	80	Ip, D. K. M. et al. The dynamic relationship between clinical symptomatology and viral
840		shedding in naturally acquired seasonal and pandemic influenza virus infections. Clin.
841		Infect. Dis. 62, 431-437, doi:10.1093/cid/civ909 (2016).
842	81	Rath, B. et al. Virus load kinetics and resistance development during oseltamivir treatment
843		in infants and children infected with Influenza A(H1N1) 2009 and Influenza B viruses.
844		Pediatr. Infect. Dis. J. 31, 899-905, doi:10.1097/INF.0b013e31825c7304 (2012).
845	82	Meschi, S. et al. Duration of viral shedding in hospitalized patients infected with pandemic
846		H1N1. BMC Infect. Dis. 11, 140, doi:10.1186/1471-2334-11-140 (2011).
847	83	Wu, U. I., Wang, J. T., Chen, Y. C. & Chang, S. C. Severity of pandemic H1N1 2009
848		influenza virus infection may not be directly correlated with initial viral load in upper
849		respiratory tract. Influenza Other Respir. Viruses 6, 367-373, doi:10.1111/j.1750-
850		2659.2011.00300.x (2012).
851	84	Yang, J. R., Lo, J., Ho, Y. L., Wu, H. S. & Liu, M. T. Pandemic H1N1 and seasonal H3N2
852		influenza infection in the human population show different distributions of viral loads,
853		which substantially affect the performance of rapid influenza tests. Virus Res. 155, 163-
854		167, doi:10.1016/j.virusres.2010.09.015 (2011).
855	85	Launes, C. et al. Viral load at diagnosis and influenza A H1N1 (2009) disease severity in
856		children. Influenza Other Respir. Viruses 6, e89-92, doi:10.1111/j.1750-
857		2659.2012.00383.x (2012).

858	86	Killingley, B. et al. Virus shedding and environmental deposition of novel A (H1N1)
859		pandemic influenza virus: interim findings. Health Technol. Assess. 14, 237-354,
860		doi:10.3310/hta14460-04 (2010).
861	87	Lee, N. et al. Viral clearance and inflammatory response patterns in adults hospitalized for
862		pandemic 2009 influenza A(H1N1) virus pneumonia. Antivir. Ther. 16, 237-247,
863		doi:10.3851/IMP1722 (2011).
864	88	Chan, P. K. et al. Clinical and virological course of infection with haemagglutinin D222G
865		mutant strain of 2009 pandemic influenza A (H1N1) virus. J. Clin. Virol. 50, 320-324,
866		doi:10.1016/j.jcv.2011.01.013 (2011).
867	89	Hung, I. F. et al. Effect of clinical and virological parameters on the level of neutralizing
868		antibody against pandemic influenza A virus H1N1 2009. Clin. Infect. Dis. 51, 274-279,
869		doi:10.1086/653940 (2010).
870	90	To, K. K. et al. Delayed clearance of viral load and marked cytokine activation in severe
871		cases of pandemic H1N1 2009 influenza virus infection. Clin. Infect. Dis. 50, 850-859,
872		doi:10.1086/650581 (2010).
873	91	Thai, P. Q. et al. Pandemic H1N1 virus transmission and shedding dynamics in index case
874		households of a prospective Vietnamese cohort. J. Infect. 68, 581-590,
875		doi:10.1016/j.jinf.2014.01.008 (2014).
876	92	Ito, M. et al. Detection of pandemic influenza A (H1N1) 2009 virus RNA by real-time
877		reverse transcription polymerase chain reaction. <i>Pediatr. Int.</i> <b>54</b> , 959-962,
878		doi:10.1111/j.1442-200X.2012.03720.x (2012).

879 93 Li, I. W. et al. The natural viral load profile of patients with pandemic 2009 influenza 880 A(H1N1) and the effect of oseltamivir treatment. Chest 137, 759-768, 881 doi:10.1378/chest.09-3072 (2010). 882 94 Esposito, S. et al. Viral shedding in children infected by pandemic A/H1N1/2009 influenza 883 virus. Virol J. 8, 349, doi:10.1186/1743-422X-8-349 (2011). 884 95 Lee, C. K. et al. Comparison of pandemic (H1N1) 2009 and seasonal influenza viral loads, 885 Singapore. Emerg. Infect. Dis. 17, 287-291, doi:10.3201/eid1702.100282 (2011). 886 96 Cowling, B. J. et al. Comparative epidemiology of pandemic and seasonal influenza A in 887 households. N. Engl. J. Med. 362, 2175-2184, doi:10.1056/NEJMoa0911530 (2010). 888 97 To, K. K. et al. Viral load in patients infected with pandemic H1N1 2009 influenza A 889 virus. J. Med. Virol. 82, 1-7, doi:10.1002/jmv.21664 (2010). 890 98 Alves, V. R. G. et al. Influenza A(H1N1)pdm09 infection and viral load analysis in 891 patients with different clinical presentations. Mem. Inst. Oswaldo Cruz 115, e200009, 892 doi:10.1590/0074-02760200009 (2020). 893 99 Cheng, P. K. et al. Performance of laboratory diagnostics for the detection of influenza 894 A(H1N1)v virus as correlated with the time after symptom onset and viral load. J. Clin. 895 Virol. 47, 182-185, doi:10.1016/j.jcv.2009.11.022 (2010). 896 100 Ngaosuwankul, N. et al. Influenza A viral loads in respiratory samples collected from 897 patients infected with pandemic H1N1, seasonal H1N1 and H3N2 viruses. Virol J. 7, 75, 898 doi:10.1186/1743-422X-7-75 (2010). 899 101 Duchamp, M. B. et al. Pandemic A(H1N1)2009 influenza virus detection by real time RT-900 PCR: is viral quantification useful? Clin. Microbiol. Infect. 16, 317-321, 901 doi:10.1111/j.1469-0691.2010.03169.x (2010).

902 102 Watanabe, M., Nukuzuma, S., Ito, M. & Ihara, T. Viral load and rapid diagnostic test in 903 patients with pandemic H1N1 2009. Pediatr. Int. 53, 1097-1099, doi:10.1111/j.1442-904 200X.2011.03489.x (2011). 905 Warnke, P., Warning, L. & Podbielski, A. Some are more equal - a comparative study on 906 swab uptake and release of bacterial suspensions. *PLoS One* **9**, e102215, 907 doi:10.1371/journal.pone.0102215 (2014). 908 Wan, X., Wang, W., Liu, J. & Tong, T. Estimating the sample mean and standard deviation 909 from the sample size, median, range and/or interquartile range. BMC Med. Res. Methodol. 910 14, 135, doi:10.1186/1471-2288-14-135 (2014). 911 Adam, D. C. et al. Clustering and superspreading potential of SARS-CoV-2 infections in 912 Hong Kong. Nat. Med., doi:10.1038/s41591-020-1092-0 (2020). 913 106 Riou, J. & Althaus, C. L. Pattern of early human-to-human transmission of Wuhan 2019 914 novel coronavirus (2019-nCoV), December 2019 to January 2020. Euro Surveill. 25, 915 doi:10.2807/1560-7917.ES.2020.25.4.2000058 (2020). 916 107 Zhang, Y., Li, Y., Wang, L., Li, M. & Zhou, X. Evaluating transmission heterogeneity and 917 super-spreading event of COVID-19 in a metropolis of China. Int. J. Environ. Res. Public 918 Health 17, doi:10.3390/ijerph17103705 (2020). 919 Tariq, A. et al. Real-time monitoring the transmission potential of COVID-19 in 108 920 Singapore, March 2020. BMC Med. 18, 166, doi:10.1186/s12916-020-01615-9 (2020). 921 Baccam, P., Beauchemin, C., Macken, C. A., Hayden, F. G. & Perelson, A. S. Kinetics of 922 influenza A virus infection in humans. J. Virol. **80**, 7590-7599, doi:10.1128/JVI.01623-05 923 (2006).

924 110 Ikeda, H. et al. Quantifying the effect of Vpu on the promotion of HIV-1 replication in the 925 humanized mouse model. Retrovirology 13, 23, doi:10.1186/s12977-016-0252-2 (2016). 926 111 Wells, W. F. On air-borne infection: study II. droplets and droplet nuclei. Am. J. 927 Epidemiol. 20, 611-618, doi:10.1093/oxfordjournals.aje.a118097 (1934). 928 112 Nicas, M., Nazaroff, W. W. & Hubbard, A. Toward understanding the risk of secondary 929 airborne infection: emission of respirable pathogens. J. Occup. Environ. Hyg. 2, 143-154, 930 doi:10.1080/15459620590918466 (2005). 931 Stadnytskyi, V., Bax, C. E., Bax, A. & Anfinrud, P. The airborne lifetime of small speech 932 droplets and their potential importance in SARS-CoV-2 transmission. Proc. Natl. Acad. 933 Sci. U. S. A. 117, 11875-11877, doi:10.1073/pnas.2006874117 (2020). 934 114 Institute, T. F. G. Guidelines for design and construction of health care facilities. (The 935 American Institute of Architects, 2006). 936 Yan, J. et al. Infectious virus in exhaled breath of symptomatic seasonal influenza cases 937 from a college community. Proc. Natl. Acad. Sci. U. S. A. 115, 1081-1086, 938 doi:10.1073/pnas.1716561115 (2018). 939 116 McDevitt, J. J. et al. Development and performance evaluation of an exhaled-breath 940 bioaerosol collector for influenza virus. Aerosol Sci. Technol. 47, 444-451, 941 doi:10.1080/02786826.2012.762973 (2013). 942 117 van Doremalen, N. et al. Aerosol and surface stability of SARS-CoV-2 as compared with 943 SARS-CoV-1. N. Engl. J. Med. 382, 1564-1567, doi:10.1056/NEJMc2004973 (2020). 944 118 Loudon, R. G. & Roberts, R. M. Droplet expulsion from the respiratory tract. Am. Rev. 945 Respir. Dis. 95, 435-442, doi:10.1164/arrd.1967.95.3.435 (1967).

947

948

949

950

951

952

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967


968

119 Duguid, J. P. The size and the duration of air-carriage of respiratory droplets and dropletnuclei. J. Hyg. (Lond.) 44, 471-479, doi:10.1017/s0022172400019288 (1946). 120 Morawska, L. et al. Size distribution and sites of origin of droplets expelled from the human respiratory tract during expiratory activities. J. Aerosol Sci 40, 256-269, doi:10.1016/j.jaerosci.2008.11.002 (2009). 121 Asadi, S. et al. Aerosol emission and superemission during human speech increase with voice loudness. Sci. Rep. 9, 2348, doi:10.1038/s41598-019-38808-z (2019). Acknowledgements We thank T. Alba (Toronto) for discussion on statistical methods. We thank E. Lavezzo and A. Chrisanti (Padova) for responses to data inquiries. This work was supported by the Natural Sciences and Engineering Research Council of Canada (NSERC) and the Toronto COVID-19 Action Fund. P.Z.C. was supported by the NSERC Vanier Scholarship (608544). D.N.F. was supported by the Canadian Institutes of Health Research (Canadian COVID-19 Rapid Research Fund, OV4-170360). F.X.G. was supported by the NSERC Senior Industrial Research Chair. **Author contributions** P.Z.C. designed the study, performed analyses, interpreted results and drafted the manuscript. P.Z.C. and N.B. conducted screening, appraised studies and drafted the review protocol. Z.P. developed and conducted the systematic review search. M.K. and D.N.F. assessed methods, interpreted results and contributed to the discussion. All authors reviewed and revised the manuscript. F.X.G. secured funds, interpreted results and supervised the project.


**Competing interests** The authors declare no competing interests.

**Supplementary information** is available for this paper.

Correspondence and requests for materials should be addressed to F.X.G.




Extended Data Fig. 1. Meta-analysis of respiratory viral loads of SARS-CoV-2, SARS-CoV-1 and influenza A(H1N1)pdm09 during the infectious period. Random-effects meta-analyses comparing the expected rVLs for COVID-19, SARS and A(H1N1)pdm09 cases during the infectious period. Quantitative specimen measurements were used to estimate rVLs, which refer to virus concentrations in the respiratory tract. Case types: hospitalized (H), not admitted (N), community (C), adult (A), pediatric (P), symptomatic (S), presymptomatic (Ps) and asymptomatic (As). Specimen types: endotracheal aspirate (ETA), nasopharyngeal aspirate (NPA), nasopharyngeal swab (NPS), oropharyngeal swab (OPS), posterior oropharyngeal saliva (POS) and sputum (Spu). Studies after ref. 35 are listed in Methods. Dashes denote case numbers that were not obtained. Box sizes are proportional to weighting in the overall estimates. Two-sided Welch's *t*-test (relative to SARS-CoV-2), non-significance (*p*>0.05).




Extended Data Fig. 2. Respiratory viral loads for SARS-CoV-2, SARS-CoV-1 and A(H1N1)pdm09 best conform to Weibull distributions. a-d, Normal  $(p \le 0.01)$  (a), lognormal  $(p \le 0.01)$  (b), gamma  $(p \le 0.005)$  (c) and Weibull (p > 0.10), not significant [NS]) (d) probability


plots for individual sample data of SARS-CoV-2 rVLs across DFSO in the systematic dataset (n=916 samples from n=19 studies). **e-h**, Normal (p>0.10, NS) (**e**), lognormal (p<0.01) (**f**), gamma (p>0.05, NS) (**g**) and Weibull (p>0.10, NS) (**h**) probability plots for individual sample data of SARS-CoV-1 rVLs in the systematic dataset (n=303 samples from n=5 studies). **i-l**, Normal (p<0.01) (**i**), lognormal (p<0.01) (**j**), gamma (p<0.005) (**k**) and Weibull (p>0.10, NS) (**l**) probability plots for individual sample data of A(H1N1)pdm09 rVLs in the systematic dataset (n=512 samples from n=10 studies). These categories included only rVL data from positive (above the detection limit) qRT-PCR measurements. The p-values were determined using the modified Kolmogorov-Smirnov test for the goodness of fit of the distributions. When the null hypothesis is accepted (NS at p>0.05), the probability density function cannot be rejected to describe the distribution of the data. Blue circles, black lines and red lines represent individual sample data, expected distributions and 95% CIs, respectively. **m-o**, Histograms and fitted Weibull distributions of the above data for SARS-CoV-2 (**m**), SARS-CoV-1 (**n**) and A(H1N1)pdm09 (**o**).



Extended Data Fig. 3. Respiratory viral loads across case percentiles for viruses, subgroups and days from symptom onset. a, b, Estimated rVLs of SARS-CoV-2 (a), SARS-CoV-1 (b) and A(H1N1)pdm09 (c) across cp during the infectious periods. d-g, Estimated SARS-CoV-2 rVLs across cp for adult (d), pediatric (e), symptomatic/presymptomatic (f) and asymptomatic (g) cases during the infectious period. h-s, Estimated SARS-CoV-2 rVLs across cp on different days of the infectious period. Earlier presymptomatic days were excluded based on limited data. Data ranged between the 1<sup>st</sup> and 99<sup>th</sup> cps. Sample numbers, distribution parameters and descriptive statistics are summarized in Extended Data Table 2. Lines and bands represent estimates and 95% CIs, respectively.




Extended Data Fig. 4. Rate profiles for particle expelled by respiratory activities. a,b, Rate profiles of particles expelled during coughing. The data were obtained from Loudon and Roberts<sup>118</sup> (a) and Duguid<sup>119</sup> (b). c, Rate profile of particles expelled during singing, as obtained from Morawaska et al<sup>120</sup>. d,e, Rate profiles of particles expelled during talking. The data were obtained from Asadi et al<sup>121</sup> (d) and Morawaska et al<sup>120</sup>. (e). f, Rate profiles of particles expelled during breathing at a natural pace, as obtained from Morawaska et al<sup>120</sup>. Insets, particle profiles with a logarithmic axis for diameter during atomization.



Extended Data Fig. 5. Heterogeneity in shedding SAR-CoV-2 via talking, breathing and coughing. a-c, Case heterogeneity in the total SARS-CoV-2 shedding rate (over all particle

sizes) by talking at a moderate level (a), breathing (b) or coughing (c) for COVID-19 cases across the infectious period. Earlier presymptomatic days were excluded based on limited data. Data represent estimated rates for viable virus and range between the 1st and 99th cps. Lines and bands represent estimates and 95% CIs, respectively.



Extended Data Fig. 6. Heterogeneity in respiratory virus shedding for subgroup COVID-19, SARS and A(H1N1)pdm09 cases. a-d, Case heterogeneity in the total SARS-CoV-2 shedding rate for adult (a), pediatric (b), symptomatic/presymptomatic (c) and asymptomatic (d) COVID-19 cases via talking, singing, breathing and coughing during the infectious period. e,f, Case heterogeneity in the total SARS-CoV-1 (e) and A(H1N1)pdm09 (f) shedding rates via talking, singing, breathing and coughing for SARS and A(H1N1)pdm09 cases, respectively, during the infectious periods. Data represent estimated rates for viable virus and range between the 1st and 99th cps. Lines and bands represent estimates and 95% CIs, respectively.

## 1039 Extended Data Table 1 I Characteristics of included studies

Study*	Country	No. of cases included (no. of specimens)	No. of pediatric cases (no. of specimens)	No. of asymptomatic cases (no. of specimens)	Disease caused by virus	Case definition (WHO)	Pharmaco- therapy (type) <sup>†</sup>	Individual data extracted (diluent volume reported) <sup>‡</sup>	Adjusted viral load <sup>§</sup> (type of specimen)	Weight, % (meta-analysis category) <sup>∥</sup>	Weight, % (meta- regression)	Risk of bias <sup>¶</sup>
Argyropoulos et al. (2020) <sup>57</sup>	USA	205 (205)	0	0	COVID-19	Confirmed	No	No (no)	Yes (NPS)	2.3 (V), 2.9 (A), 2.5 (S/Ps)	2.12	*****
Baggio et al. (2020) <sup>55</sup>	Switzerland	405 (405)	58 (58)	0	COVID-19	Confirmed	No	Yes (no)	Yes (NPS)	2.1 (V), 2.7 (A), 11.5 (P), 2.2 (S/Ps)	4.18	*****
Fajnzylber et al. (2020) <sup>47</sup>	USA	- (31)	0	0	COVID-19	Confirmed	No	Yes (yes)	Yes (NPS, OPS) No (Spu)	2.8 (V), 3.5 (A), 3.0 (S/Ps)	0.32	******
Han et al. (2020) <sup>65</sup>	South Korea	2 (8)	1 (6)	0	COVID-19	Confirmed	No	Yes (no)	Yes (NPS, OPS)	2.7 (V), 2.8 (S/Ps)	0.08	*****
Han et al. (2020) <sup>63</sup>	South Korea	12 (27)	12 (27)	3 (7)	COVID-19	Confirmed	No	Yes (no)	Yes (NPS)	3.2 (V), 18.5 (P), 3.2 (S/Ps), 31.0 (As)	0.28	******
Hung et al. (2020) <sup>52</sup>	China	41 (310)	0	0	COVID-19	Confirmed	No (control group)	No (no)	Yes (NPS, OPS, POS)	2.0 (V), 2.4 (A), 2.1 (S)	3.20	******
Hurst et al. (2020) <sup>61</sup>	USA	133 (133)	54 (54)	52 (52)	COVID-19	Confirmed	No	Yes (no)	Yes (NPS)	2.8 (V), 15.3 (P), 3.0 (S/Ps), 24.1 (As)	1.37	******
lwasaki et al. (2020) <sup>53</sup>	Japan	5 (5)	0	0	COVID-19	Confirmed	No	Yes (no)	Yes (NPS)	4.2 (V), 5.2 (A), 4.5 (S/Ps)	0.05	***
Kawasuji et al. (2020) <sup>66</sup>	Japan	16 (16)	-	-	COVID-19	Confirmed	Yes (antivirals - type not reported)	Yes (no)	Yes (NPS)	2.8 (V)	0.18	****
L'Huillier et al. (2020) <sup>62</sup>	Switzerland	23 (23)	23 (23)	0	COVID-19	Confirmed	No	Yes (no)	Yes (NPS)	1.5 (V), 8.4 (P), 1.6 (S/Ps)	0.24	******
Lavezzo et al. (2020) <sup>43</sup>	Italy	103 (110)	2 (3)	49 (49)	COVID-19	Confirmed	No	Yes (yes)	Yes (NPS, OPS)	3.2 (V), 4.0 (A), 14.4 (P), 3.3 (S/Ps), 27.9 (A)	1.13	*****
Lennon et al. (2020) <sup>49</sup>	USA	2,200 (2,200)	18 (18)	2,200 (2,200#)	COVID-19	Confirmed	No	No (yes)	Yes (NPS)	2.0 (V), 2.5 (A), 17.0 (As)	22.70	*****
Lucas et al. (2020) <sup>56</sup>	USA	24 (33)	0	0	COVID-19	Confirmed	Moderate and severe patients (tocilizumab)	Yes (yes)	Yes (NPS)	3.3 (V), 4.0 (A), 3.5 (S/Ps)	0.34	*****
Mitja et al. (2020) <sup>58</sup>	Spain	148 (296)	0	0	COVID-19	Confirmed	No (control group)	No (no)	Yes (NPS)	1.9 (V), 2.3 (A), 2.0 (S/Ps)	3.05	******
Pan et al. (2020) <sup>64</sup>	China	75 (104)	-	0	COVID-19	Confirmed	No	Yes (no)	Yes (OPS) No (Spu)	0.7 (V), 0.7 (S/Ps)	1.07	****

Peng et al. (2020) <sup>44</sup>	China	6 (6)	0	0	COVID-19	Confirmed	Yes (arbidol, lopinavir, ritonavir)	Yes (no)	Yes (OPS)	6.6 (V), 8.2 (A), 7.1 (S/Ps)	0.06	*****
Perera et al. (2020) <sup>54</sup>	China	- (36)	0	-	COVID-19	Confirmed	No	Yes (no)	Yes (NPA, NPS, OPS, Spu)	1.5 (V), 1.8 (A)	0.39	****
Shi et al. (2020) <sup>51</sup>	China	103 (103)	0	0	COVID-19	Confirmed	No	Yes (no)	Yes (NPS, OPS)	19.0 (V), 23.4 (A), 20.2 (S/Ps)	1.06	****
Shrestha et al. (2020) <sup>50</sup>	USA	171 (171)	0	0	COVID-19	Confirmed	No	Yes (no)	Yes (NPS)	2.4 (V), 3.0 (A), 2.6 (S/Ps)	1.76	*****
To et al. (2020) <sup>45</sup>	China	23 (51)	0	0	COVID-19	Confirmed	No	Yes (yes)	Yes (ETA, POS)	1.5 (V), 1.8 (A), 1.6 (S/Ps)	0.53	******
van Kampen et al. (2020) <sup>35</sup>	The Netherlands	- (154)	0	0	COVID-19	Confirmed	No	Yes (yes)	Yes (NPS, Spu)	3.2 (V), 4.0 (A), 3.5 (S/Ps)	1.59	*****
Vetter et al. (2020) <sup>59</sup>	Switzerland	5 (63)	0	0	COVID-19	Confirmed	No	Yes (yes)	Yes (NPS, OPS)	3.3 (V), 4.1 (A), 3.5 (S/Ps)	0.65	******
Wölfel et al. (2020) <sup>13</sup>	Germany	9 (136)	0	1 (4)	COVID-19	Confirmed	No	Yes (yes)	Yes (NPS, OPS) No (Spu)	2.5 (V), 3.0 (A), 3.2 (S)	1.37	*****
Xu et al. (2020) <sup>60</sup>	China	7 (14)	7 (14)	1 (1)	COVID-19	Confirmed	No	Yes (no)	Yes (NPS)	5.5 (V), 31.8 (P), 5.8 (S/Ps),	0.14	*****
Zhang et al. (2020) <sup>42</sup>	China	9 (9)	0	0	COVID-19	Confirmed	No	Yes (no)	Yes (NPS, OPS)	4.0 (V), 5.0 (A), 4.3 (S/Ps)	0.09	*****
Zheng et al. (2020) <sup>48</sup>	China	- (19)	0	0	COVID-19	Confirmed	No	Yes (no)	Yes (POS, Spu)	10.0 (V), 12.4 (A), 10.7 (S/Ps)	0.20	*****
Zou et al. (2020) <sup>46</sup>	China	14 (55)	0	1 (4)	COVID-19	Confirmed	No	Yes (no)	Yes (NPS, OPS)	3.0 (V), 3.7 (A), 3.1 (S/Ps)	0.57	******
Chen et al. (2006) <sup>69</sup>	China	154 (154#)	0	0	SARS	Confirmed	Yes (oseltamivir, broad-spectrum antibiotics, ribavirin)	Yes (no)	Yes (NPS)	17.9 (V)	1.58	*****
Chu et al. (2004) <sup>67</sup>	China	133 (133)	0	0	SARS	Confirmed	No	No (yes)	Yes (NPA)	2.9 (V)	1.37	******
Chu et al. (2004) <sup>70</sup> ☆	China	11 (11)	0	0	SARS	Confirmed	No (control group)	Yes (yes)	Yes (NPS)	6.7 (V)	0.11	******
Chu et al. (2005) <sup>72</sup>	China	57 (57)	0	0	SARS	Confirmed	No	Yes (yes)	Yes (NPA)	11.6 (V)	0.59	******
Cheng et al. (2004) <sup>74</sup>	China	59 (59)	0	0	SARS	Confirmed	Yes (ribavirin, hydrocortisone, prednisolone, methylpredni- solone)	Yes (yes)	Yes (NPA)	14.2 (V)	0.61	*****
Hung et al. (2004) <sup>73</sup>	China	60 (60)	0	0	SARS	Confirmed	Yes (ribavirin, hydrocortisone, prednisolone,	No (yes)	Yes (NPA)	14.7 (V)	0.62	*****

							methylpredni- solone)					
Peiris et al. (2003) <sup>75 ☆</sup>	China	14 (42)	0	0	SARS	Confirmed	Yes (ribavirin, hydrocortisone, prednisolone, methylpredni- solone)	Yes (no)	Yes (NPA)	19.2 (V)	0.43	******
Poon et al. (2003) <sup>68</sup>	China	40 (40)	0	0	SARS	Confirmed	No	No (yes)	Yes (NPA)	4.6 (V)	0.41	****
Poon et al. (2004) <sup>71</sup>	China	- (43)	0	0	SARS	Confirmed	-	No (yes)	Yes (NPA)	8.2 (V)	0.44	****
Alves et al. (2020)98	Brazil	86 (86)	-	15 (15)	Influenza A(H1N1)pdm09	Confirmed	No	No (yes)	Yes (NPA, NPS, OPS)	2.4 (V)	0.89	****
Chan et al. (2011) <sup>88</sup>	China	58 (58)	0	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	Yes (no)	Yes (NPA, NPS, OPS)	4.6 (V)	0.60	*****
Cheng et al. (2010) <sup>99</sup>	China	60 (60)	-	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (no)	Yes (NPA)	3.3 (V)	0.62	*****
Cowling et al. (2010) <sup>96</sup>	China	45 (54)	22 (31)	0	Influenza A(H1N1)pdm09	Confirmed	Yes (22 cases on oseltamivir)	Yes (yes)	Yes (NPS, OPS)	3.1 (V)	0.56	*****
Duchamp et al. (2010) <sup>101</sup>	France	209 (209)	209 (209)	0	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir, zanamivir)	No (yes)	Yes (NPS)	2.4 (V)	2.16	****
Esposito et al. (2011) <sup>94</sup>	Italy	74 (282)	74 (282)	0	Influenza A(H1N1)pdm09	Confirmed	No	Yes (yes)	Yes (NPS)	2.2 (V)	2.91	*****
Hung et al. (2010) <sup>89</sup>	China	87 (87)	-	0	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir)	Yes (no)	Yes (NPA, NPS)	4.7 (V)	0.90	*****
lp et al. (2016) <sup>80</sup>	China	17 (20)	7 (-)	0	Influenza A(H1N1)pdm09	Confirmed	No	Yes (no)	Yes (NPS, OPS)	5.0 (V)	0.21	*****
Ito et al. (2012) <sup>92</sup>	Japan	34 (34)	-	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	Yes (yes)	Yes (NPS)	5.5 (V)	0.35	****
Killingley et al. (2010)86	United Kingdom	12 (21)	-	0	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir)	Yes (yes)	Yes (NPS)	3.3 (V)	0.22	*****
Launes et al. (2012)85	Spain	47 (47)	47 (47)	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (no)	Yes (NPA)	3.0 (V)	0.48	*****
Lee et al. (2011) <sup>87</sup>	China	48 (48)	0	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (no)	Yes (NPA)	4.1 (V)	0.50	*****
Lee et al. (2011) <sup>95</sup>	Singapore	578 (578)	231 (231)	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (no)	Yes (NPS)	4.1 (V)	5.96	******
Li et al. (2010) <sup>78</sup>	China	581 (581)	522 (522)	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (no)	Yes (OPS)	6.7 (V)	5.99	*****
Li et al. (2010) <sup>93</sup>	China	27 (59)	-	0	Influenza A(H1N1)pdm09	Confirmed	No (non-treated group)	No (no)	Yes (NPA, NPS, OPS)	3.8 (V)	0.61	*****
Loeb et al. (2012) <sup>76</sup>	Canada	97 (218)	-	- (17)	Influenza A(H1N1)pdm09	Confirmed	No	No (no)	Yes (NPS)	4.9 (V)	2.25	*****

et al. 12) <sup>79</sup>	China	13 (25)	-	0	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir, zanamivir)	Yes (no)	Yes (NPS)	2.4 (V)	0.26	*****
schi et al. 11) <sup>82</sup>	Italy	533 (533)	0	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (no)	Yes (NPS)	4.8 (V)	5.50	******
aosuwankul al. (2010) <sup>100</sup>	China	12 (33)	-	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (yes)	Yes (NPA, NPS, OPS)	2.8 (V)	0.34	*****
h et al. 12) <sup>81</sup>	Germany	27 (41)	27 (41)	0	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir)	Yes (yes)	Yes (NPS)	4.1 (V)	0.42	******
ess et al. 10) <sup>77</sup>	Germany	51 (129)	12 (-)	1 (1)	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir)	No (no)	Yes (NPA, NPS, OPS)	2.4 (V)	1.33	*****
ai et al. 14) <sup>91</sup>	Vietnam	33 (123)	16 (-)	5 (28)	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir)	Yes (yes)	Yes (NPS)	5.8 (V)	1.27	*****
et al. 10) <sup>90</sup>	China	50 (50)	0	0	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir, nebulized zanamivir)	No (no)	Yes (NPA, NPS)	2.2 (V)	0.52	*****
et al. 10) <sup>97</sup>	China	22 (22)	-	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (no)	Yes (NPA, NPS, OPS)	2.5 (V)	0.23	****
tanabe et (2011) <sup>102</sup>	Japan	251 (251)	251 (251)	0	Influenza A(H1N1)pdm09	Confirmed	No (pretreatment)	No (yes)	Yes (NPA)	6.6 (V)	2.59	******
et al. 12) <sup>83</sup>	China	64 (89)	-	0	Influenza A(H1N1)pdm09	Confirmed	Yes (oseltamivir)	No (yes)	Yes (NPS)	2.3 (V)	0.92	*****
ng et al. 11) <sup>84</sup>	China	251 (251)	-	0	Influenza A(H1N1)pdm09	Confirmed	N/A	No (yes)	Yes (OPS)	0.8 (V)	6.53	*****
	12) <sup>79</sup> schi et al. 11) <sup>82</sup> aosuwankul d. (2010) <sup>100</sup> h et al. 12) <sup>81</sup> ses et al. 10) <sup>77</sup> ii et al. 10) <sup>90</sup> et al. 10) <sup>97</sup> tanabe et 2011) <sup>102</sup> et al. 12) <sup>83</sup> ag et al. 11) <sup>84</sup>	12) <sup>79</sup> China schi et al. 11) <sup>82</sup> Italy assuwankul I. (2010) <sup>100</sup> China h et al. 12) <sup>81</sup> Germany ses et al. 10) <sup>77</sup> Germany ii et al. 14) <sup>91</sup> Vietnam et al. 10) <sup>90</sup> China et al. 10) <sup>97</sup> China tanabe et 2011) <sup>102</sup> Japan et al. 12) <sup>83</sup> China ig et al. China	12) <sup>79</sup> China 13 (25)  schi et al.   11) <sup>92</sup> Italy 533 (533)  chosuwankul   1. (2010) <sup>100</sup> China 12 (33)  h et al.   12) <sup>81</sup> Germany 27 (41)  ses et al.   10) <sup>77</sup> Germany 51 (129)  si et al.   14) <sup>91</sup> Vietnam 33 (123)  et al.   10) <sup>90</sup> China 50 (50)  et al.   10) <sup>97</sup> China 22 (22)  tanabe et   2011) <sup>102</sup> Japan 251 (251)  et al.   12) <sup>83</sup> China 64 (89)  si et al.   12) <sup>83</sup> China 251 (251)	12) <sup>79</sup> China 13 (25) -  Schi et al. Italy 533 (533) 0  Schi et al. 11) <sup>82</sup> Italy 533 (533) 0  Schi et al. 12 (33) -  He et al. 12) <sup>81</sup> Germany 27 (41) 27 (41)  Sess et al. 10) <sup>77</sup> Germany 51 (129) 12 (-)  Schi et al. 14) <sup>91</sup> Vietnam 33 (123) 16 (-)  Schi et al. 10) <sup>90</sup> China 50 (50) 0  Schi al. 10) <sup>97</sup> China 22 (22) -  Schi al. 10) <sup>97</sup> China 22 (22) -  Schi al. 10) <sup>97</sup> China 251 (251) 251 (251)  Schi al. 12) <sup>83</sup> China 64 (89) -  Schi al. 12) <sup>83</sup> China 251 (251) -  Schi al. 12) <sup>83</sup> China 251 (251) -	12) <sup>79</sup> China 13 (25) - 0  schi et al. 11) <sup>82</sup> Italy 533 (533) 0 0 0  assuwankul I. (2010) <sup>100</sup> China 12 (33) - 0  he t al. 12) <sup>81</sup> Germany 27 (41) 27 (41) 0  sss et al. 10) <sup>77</sup> Germany 51 (129) 12 (-) 1 (1)  ii et al. 14) <sup>91</sup> Vietnam 33 (123) 16 (-) 5 (28)  et al. 10) <sup>90</sup> China 50 (50) 0 0  et al. 10) <sup>97</sup> China 22 (22) - 0  tanabe et 2011) <sup>102</sup> Japan 251 (251) 251 (251) 0  et al. 12) <sup>83</sup> China 64 (89) - 0  ig et al. 11) <sup>84</sup> China 251 (251) - 0	12 79	12) <sup>79</sup>   China   13 (25)   -	China   13 (25)   -	A(H1N1)pdm09   Confirmed   Zanamivir)   Yes (no)	A(H1N1)pdm09   Confirmed   Zanamivir)   Yes (NPS)	A(H1N1)pdm09   Confirmed   Zanamivir)   Yes (NO)   Yes (NPS)   2.4 (V)	China   13 (25)   -

<sup>\*</sup>References 13 and 35 are listed in the main body while those 42 and after are listed in Methods. Data shown as "-" were not obtained from the paper or authors.

<sup>†</sup>Responses of "no" for pharmacotherapy are based on no pharmacotherapy given to any patients or none reported in the study.

<sup>‡</sup>For studies reporting specimen measurements as individual sample data (either in numerical or graphical formats), the sample data was extracted for analysis.

<sup>§</sup>Specimen measurements were converted to rVLs based on the dilution factor for specimens immersed in transport media.

<sup>&</sup>quot;Abbreviations: viral meta-analysis (V), adult subgroup (A), pediatric subgroup (P), symptomatic/presymptomatic subgroup (S/Ps), asymptomatic subgroup (As).

The hybrid JBI Critical Appraisal Checklist was used, with more stars indicating lower risk of bias. Results from each study are shown in Supplementary Table 6.

<sup>\*</sup>For these studies, only 2,147 (Lennon et al.) and 134 (Chen et al.) individual specimen measurements were obtained for the individual sample datasets.

For Chu et al., only specimen measurements at 20 DFSO were extracted, as 5-15 DFSO were equivalent specimens as those reported in Peiris et al.

Extended Data Table 2 | Descriptive parameters for subgroups of respiratory viral loads based on individual sample data

			Weibull distributi	on parameters	Respiratory viral	load, log	o copies/ml		
Category	n * (specimens)	n * (studies)	Scale factor (95% CI)	Shape factor (95% CI)	Mean (95% CI)†	SD†	90th percentile (95% CI) <sup>‡</sup>	95 <sup>th</sup> percentile (95% CI) <sup>‡</sup>	99th percentile (95% CI) <sup>‡</sup>
SARS-CoV-2 (overall)§	3,778	24	7.01 (6.94-7.07)	3.47 (3.38-3.56)	6.28 (6.22-6.35)	2.04	8.91 (8.82-9.00)	9.61 (9.51-9.71)	10.88 (10.75-11.02)
SARS-CoV-1 (overall)§	303	5	6.34 (6.12-6.56)	3.37 (3.09-3.68)	5.69 (5.48-5.90)	1.86	8.11 (7.83-8.40)	8.77 (8.45-9.11)	9.96 (9.54-10.41)
A(H1N1)pdm09 (overall)§	512	10	7.39 (7.27-7.51)	5.43 (5.07-5.81)	6.81 (6.69-6.94)	1.45	8.62 (8.47-8.76)	9.04 (8.88-9.21)	9.79 (9.59-10.00)
SARS-CoV-2 (adult)§	3,532	18	6.99 (6.92-7.06)	3.47 (3.38-3.56)	6.27 (6.20-6.34)	2.04	8.89 (8.80-8.98)	9.59 (9.49-9.70)	10.86 (10.72-11.00)
SARS-CoV-2 (pediatric)§	185	7	7.47 (7.17-7.79)	3.65 (3.26-4.08)	6.73 (6.43-7.02)	2.06	9.39 (9.01-9.79)	10.09 (9.65-10.56)	11.36 (10.78-11.97)
SARS-CoV-2 (symptomatic/presymptomatic)§	1,503	20	7.39 (7.28-7.49)	3.79 (3.64-3.94)	6.66 (6.56-6.76)	2.01	9.21 (9.08-9.34)	9.87 (9.72-10.02)	11.06 (10.86-11.26)
SARS-CoV-2 (asymptomatic)§	2,212	6	6.72 (6.63-6.81)	3.32 (3.22-3.44)	6.01 (5.93-6.09)	2.02	8.64 (8.52-8.75)	9.35 (9.21-9.48)	10.64 (10.46-10.81)
SARS-CoV-2 (all DFSO)§	916	19	7.04 (6.90-7.18)	3.47 (3.30-3.65)	6.32 (6.19-6.45)	2.04	8.95 (8.78-9.13)	9.66 (9.45-9.86)	10.93 (10.66-11.21)
SARS-CoV-2 (-3 DFSO) <sup>II</sup>	1	1	-	-	10.34	-	-	-	-
SARS-CoV-2 (-2 DFSO) <sup>II</sup>	3	2	-	-	4.22 (2.41-6.02)	1.59	-	-	-
SARS-CoV-2 (-1 DFSO)	15	5	6.17 (5.11-7.47)	2.82 (1.89-4.19)	5.48 (4.25-6.70)	2.21	8.30 (6.88-10.02)	9.11 (7.44-11.16)	10.62 (8.38-13.45)
SARS-CoV-2 (0 DFSO)	48	10	6.63 (6.08-7.23)	3.46 (2.81-4.26)	5.97 (5.43-6.51)	1.85	8.43 (7.75-9.18)	9.10 (8.32-9.96)	10.31 (9.29-11.43)
SARS-CoV-2 (1 DFSO)	59	10	7.79 (7.23-8.40)	3.58 (2.91-4.40)	7.00 (6.42-7.59)	2.26	9.83 (9.12-10.61)	10.58 (9.75-11.49)	11.93 (10.84-13.14)
SARS-CoV-2 (2 DFSO)¶	69	13	7.42 (6.93-7.95)	3.61 (2.97-4.39)	6.67 (6.15-7.19)	2.17	9.35 (8.72-10.03)	10.06 (9.32-10.85)	11.33 (10.35-12.40)
SARS-CoV-2 (3 DFSO)¶	71	15	7.27 (6.74-7.84)	3.25 (2.69-3.93)	6.50 (5.96-7.04)	2.29	9.39 (8.71-10.14)	10.19 (9.38-11.06)	11.63 (10.54-12.82)
SARS-CoV-2 (4 DFSO)¶	81	15	6.84 (6.27-7.45)	2.66 (2.22-3.17)	6.08 (5.52-6.63)	2.51	9.36 (8.58-10.21)	10.34 (9.40-11.36)	12.15 (10.87-13.59)
SARS-CoV-2 (5 DFSO)¶	87	14	7.16 (6.67-7.68)	3.14 (2.65-3.72)	6.40 (5.91-6.89)	2.29	9.33 (8.69-10.02)	10.15 (9.40-10.96)	11.64 (10.63-12.74)
SARS-CoV-2 (6 DFSO)¶	102	14	6.81 (6.37-7.27)	3.09 (2.63-3.62)	6.07 (5.63-6.51)	2.24	8.92 (8.34-9.53)	9.71 (9.03-10.44)	11.16 (10.24-12.17)
SARS-CoV-2 (7 DFSO)¶	125	18	6.50 (6.13-6.89)	3.10 (2.69-3.58)	5.82 (5.45-6.19)	2.10	8.50 (8.01-9.03)	9.26 (8.67-9.88)	10.63 (9.84-11.49)
SARS-CoV-2 (8 DFSO)¶	119	18	6.49 (6.09-6.91)	2.99 (2.59-3.46)	5.79 (5.40-6.18)	2.14	8.57 (8.04-9.13)	9.35 (8.73-10.02)	10.80 (9.96-11.71)
SARS-CoV-2 (9 DFSO)¶	117	18	6.18 (5.76-6.63)	2.72 (2.35-3.15)	5.51 (5.11-5.91)	2.20	8.40 (7.82-9.01)	9.25 (8.57-9.98)	10.83 (9.90-11.85)
SARS-CoV-2 (10 DFSO)¶	110	16	5.76 (5.34-6.20)	2.61 (2.25-3.03)	5.13 (4.73-5.53)	2.11	7.92 (7.34-8.55)	8.76 (8.07-9.51)	10.33 (9.38-11.37)

<sup>\*</sup>These two columns summarize the cumulative number of specimens (left) collected from the number of studies (right) for each category in the systematic dataset.

<sup>&</sup>lt;sup>†</sup>The mean and sample SD were calculated on the entire set of individual sample data for each category.

<sup>‡</sup>The Weibull quantile distributions were used to determine rVLs at the 90th, 95th and 99th cps.

<sup>\$</sup>These categories included only rVL data from positive (above the detection limit) qRT-PCR measurements.

Data for earlier DFSO were excluded from distribution fitting based on limited data, and empty cells were marked with "-".

These categories included negative qRT-PCR measurements (set at the detection limit to estimate rVLs; n = 3, 3, 6, 8, 12, 15, 13, 17 and 14 specimens for 2-10 DFSO, respectively) for cases that tested positive at an earlier DFSO.

Extended Data Table 3 I Model parameters describing SARS-CoV-2 kinetics in the respiratory tract

Parameter	Description	Value (95% CI)	Units
β	Infection rate constant	4.02 (3.01-5.03)	×10 <sup>-7</sup> (copies/ml) <sup>-1</sup> day <sup>-1</sup>
p	Cellular shedding rate of virus	1.11 (0.51-1.71)	copies/ml day-1 cell-1
С	Clearance rate of virus	3.82 (0.17-7.47)	day <sup>-1</sup>
δ	Clearance rate of infected epithelial cells	0.55 (0.23-0.87)	day <sup>-1</sup>
<i>R</i> <sub>0,c</sub>	Cellular basic reproductive number	10.6	unitless
<i>V</i> <sub>0</sub> *	Initial rVL parameter	4	copies/ml
<i>l</i> o*	Initial number of infected cells	0	cells
$T_0^*$	Initial number of uninfected cells	5×10 <sup>7</sup>	cells

<sup>\*</sup>Initial values were used as inputs for the numerical estimation of the model parameters.

1056